<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:googleplay="http://www.google.com/schemas/play-podcasts/1.0"><channel><title><![CDATA[The Oncology Shot with Timothee Olivier]]></title><description><![CDATA[My Personal Substack]]></description><link>https://www.theoncologyshot.com</link><image><url>https://substackcdn.com/image/fetch/$s_!NOPl!,w_256,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F255e79c4-f9d2-4899-9eda-ff14160b76ce_990x976.png</url><title>The Oncology Shot with Timothee Olivier</title><link>https://www.theoncologyshot.com</link></image><generator>Substack</generator><lastBuildDate>Wed, 18 Nov 2026 09:09:43 GMT</lastBuildDate><atom:link href="https://www.theoncologyshot.com/feed" rel="self" type="application/rss+xml"/><copyright><![CDATA[Timothée Olivier]]></copyright><language><![CDATA[en]]></language><webMaster><![CDATA[timotheemd@substack.com]]></webMaster><itunes:owner><itunes:email><![CDATA[timotheemd@substack.com]]></itunes:email><itunes:name><![CDATA[Timothée Olivier]]></itunes:name></itunes:owner><itunes:author><![CDATA[Timothée Olivier]]></itunes:author><googleplay:owner><![CDATA[timotheemd@substack.com]]></googleplay:owner><googleplay:email><![CDATA[timotheemd@substack.com]]></googleplay:email><googleplay:author><![CDATA[Timothée Olivier]]></googleplay:author><itunes:block><![CDATA[Yes]]></itunes:block><item><title><![CDATA[The Risk of Uninformative Trials: Statistical Considerations in Radiotherapy Trials]]></title><description><![CDATA[In today&#8217;s guest post, I&#8217;m pleased to welcome Susannah Ellsworth, a radiation oncologist at the University of Pittsburgh and Residency Program Director at UPMC Hillman Cancer Center.]]></description><link>https://www.theoncologyshot.com/p/the-risk-of-uninformative-trials</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/the-risk-of-uninformative-trials</guid><dc:creator><![CDATA[Susannah Ellsworth]]></dc:creator><pubDate>Tue, 17 Nov 2026 16:37:57 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!z4cz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><em>In today&#8217;s guest post, I&#8217;m pleased to welcome <a href="https://radiationoncology.pitt.edu/people/susannah-g-ellsworth-md">Susannah Ellsworth</a>, a radiation oncologist at the University of Pittsburgh and Residency Program Director at UPMC Hillman Cancer Center. She expands on a recent commentary we published together and its implications for past and ongoing radiotherapy trials. Timoth&#233;e</em></p><div><hr></div><blockquote><p><em><strong>&#8220;A good decision is based on knowledge and not on numbers.&#8221; </strong></em><br>Plato, <em>Laches, or Courage</em></p></blockquote><p>Clinical trial design is fraught with difficult choices. Investigators must balance feasibility and budget considerations with the need to generate results and are often incentivized to minimize sample sizes, as smaller studies are cheaper and accrue faster. Several design choices affect sample size calculations, including effect size estimates and approach to significance testing. The essay below will discuss how these often-overlooked factors can affect clinical trial design and interpretation, expanding on issues raised in our <a href="https://www.ejcancer.com/article/S0959-8049(26)01572-8/fulltext">recent commentary</a> published in the <em>European Journal of Cancer</em>.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!z4cz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!z4cz!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 424w, https://substackcdn.com/image/fetch/$s_!z4cz!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 848w, https://substackcdn.com/image/fetch/$s_!z4cz!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 1272w, https://substackcdn.com/image/fetch/$s_!z4cz!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!z4cz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png" width="1456" height="746" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/aa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:746,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1035697,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/225306262?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!z4cz!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 424w, https://substackcdn.com/image/fetch/$s_!z4cz!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 848w, https://substackcdn.com/image/fetch/$s_!z4cz!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 1272w, https://substackcdn.com/image/fetch/$s_!z4cz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Faa61c09b-2542-47ed-87a3-b02115d8bb9d_1703x872.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>Relation between sample size and effect size</strong></h3><p>Sample size depends upon anticipated effect size and desired statistical power. This relationship can be illustrated by a hypothetical experiment evaluating two &#8220;unfair&#8221; coins: Coin A will turn up heads on 2/3 of tosses, whereas Coin B will land on heads on 51/100 tosses. After how many tosses will you feel confident that Coin A is unfair? What about Coin B? Intuitively, more tosses are needed to identify the smaller effect size associated with Coin B. Similarly, a larger projected effect size allows clinical trials to utilize a smaller sample, as shown in the graph below. </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!pSdr!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!pSdr!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 424w, https://substackcdn.com/image/fetch/$s_!pSdr!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 848w, https://substackcdn.com/image/fetch/$s_!pSdr!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 1272w, https://substackcdn.com/image/fetch/$s_!pSdr!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!pSdr!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png" width="1456" height="796" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/d568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:796,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:313152,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/225306262?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!pSdr!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 424w, https://substackcdn.com/image/fetch/$s_!pSdr!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 848w, https://substackcdn.com/image/fetch/$s_!pSdr!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 1272w, https://substackcdn.com/image/fetch/$s_!pSdr!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd568ad51-3f0b-447e-9d49-b04b70fd05df_1463x800.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Personal material (generated using Google Gemini)</figcaption></figure></div><p>Underestimating effect size leads to inefficiencies by requiring overly large sample sizes, slowing accrual and inflating budgets, whereas overly ambitious projections can cause a trial to fail to meet its primary endpoint, making effect size estimates a critical aspect of trial design. </p><blockquote><p>While clinical <strong>trialists obviously must make educated guesses</strong> regarding effect size &#8211; after all, if the true magnitude of benefit associated with an experimental therapy were known, running a clinical trial would be pointless &#8211; such <strong>estimates should still be grounded solidly in prior data.</strong></p></blockquote><h3><strong>Risks of inaccurate effect size estimates</strong></h3><p>Clinical trials are occasionally <a href="https://bmjoncology.bmj.com/content/4/1/e000931">critiqued</a> for inflating projected effect size by including a suboptimal control arm. A related but distinct issue is a study which retains equipoise, but whose inaccurate effect size estimates make it unlikely to reach its primary endpoint. </p><p>Illustrative of the consequences of unrealistic effect size estimates is NRG-GI-003, a recent randomized study demonstrating no benefit to proton versus photon SBRT for hepatocellular carcinoma (HCC); 2-year overall survival (OS) was 56.2% versus 69.3% with protons vs. photons, respectively. </p><p>Initial discussions of GI-003 characterized outcomes with photon therapy as a <a href="https://www.cancernetwork.com/view/proton-therapy-does-not-improve-survival-in-hepatocellular-carcinoma">surprising overperformance</a> relative to the study&#8217;s original projections. However, multiple other studies &#8211; all published prior to GI-003&#8217;s activation &#8211; suggest that the single paper cited to substantiate GI-003&#8217;s control-arm OS estimates was likely an outlier (Bujold 2013; Table 1). Furthermore, even as GI-003 went on accruing patients, additional data continued to emerge showing far better outcomes with photon SBRT than the trial had planned for. For example, <a href="https://www.redjournal.org/article/S0360-3016(23)07777-5/fulltext">a 2024 meta-analysis</a> of photon SBRT for HCC reported a pooled 3-year OS estimate of 57%. The study accrual period (2017-2026) also saw FDA approvals for six systemic regimens in HCC, all of which could have influenced OS among patients on GI-003, which did not protocolize systemic therapy.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!PiFL!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!PiFL!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 424w, https://substackcdn.com/image/fetch/$s_!PiFL!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 848w, https://substackcdn.com/image/fetch/$s_!PiFL!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 1272w, https://substackcdn.com/image/fetch/$s_!PiFL!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!PiFL!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png" width="964" height="470" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:470,&quot;width&quot;:964,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:37962,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/225306262?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!PiFL!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 424w, https://substackcdn.com/image/fetch/$s_!PiFL!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 848w, https://substackcdn.com/image/fetch/$s_!PiFL!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 1272w, https://substackcdn.com/image/fetch/$s_!PiFL!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82566a1c-45f0-40e2-8321-fe39750faf1b_964x470.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Personal material, references : <a href="https://pubmed.ncbi.nlm.nih.gov/20231127/">Cardenes 2010</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/20740576/">Seo 2010</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/21645977/">Andolino 2011</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/22570179/">Kang 2012</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/23547075/">Bujold 2013</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/25644863/">Scorsetti 2015</a>, <a href="https://pubmed.ncbi.nlm.nih.gov/27213593/">Kim 2016</a>.</figcaption></figure></div><blockquote><p>Clear <strong>parallels can be drawn between NRG-GI-003 and NRG-GI-011</strong>, which randomizes patients with unresectable pancreatic cancer to <strong>dose-escalated RT</strong> versus <strong>physician&#8217;s choice of continued chemotherapy, conventional chemoradiation, or observation</strong>. </p></blockquote><p>Like GI-003, GI-011 features a poorly substantiated effect size estimate; no citation at all is provided for the control arm&#8217;s two-year OS estimate of 15%, which likely <a href="https://pubmed.ncbi.nlm.nih.gov/36652891/">underestimates projected OS</a>, especially since the trial only enrolls <a href="https://www.esmoopen.com/article/S2059-7029(22)00180-6/fulltext">responders to induction chemotherapy</a>. GI-011 similarly provides no mechanism to adapt to emerging advances in systemic therapy (e.g., <a href="https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer">daraxonrasib</a>) that may affect OS, creating substantial risk that it will also fail to meet its primary endpoint.</p><h3><strong>Clinical Equipoise: One-Sided or Two-Sided Hypothesis Testing?</strong></h3><p>Sample size calculations are also affected by statistical significance considerations; statistical power decreases as sample size is reduced, assuming effect size remains constant. </p><p>Investigators can address this problem by relaxing the prespecified significance level &#945;, albeit at the cost of an increased type I error rate. Alternatively, substituting one-sided for two-sided significance testing can permit a trial to maintain statistical power with a smaller sample size. </p><blockquote><p>However, <strong>one-sided significance testing can only assess whether the magnitude of treatment effect exceeds some threshold in a single, prespecified direction</strong>. This is <strong>difficult to square with the principle of clinical equipoise</strong>, which requires genuine doubt regarding which of the arms on a randomized superiority trial is better.</p></blockquote><p>GI-003 opened under the premise that equipoise was present between proton and photon SBRT for HCC; its original design required 155 evaluable patients, providing 85% power to evaluate the primary endpoint with a <em>two-sided </em>&#945; of 0.05. However, immediately before closing, the trial underwent a major statistical revision. Sample size was reduced to 112; in order to maintain the original effect size projections, power was reduced to 80%, and one-sided significance testing substituted for two-sided. Ad hoc revision of the statistical approach in this way is difficult to justify, especially since this change foreclosed any possibility of assessing whether there was in fact <em>harm</em> from proton SBRT, which was associated with numerically inferior OS. Similarly, GI-011 utilizes one-sided significance testing, not only raising the same questions about whether this statistical approach is consistent with clinical equipoise in a randomized superiority study but likewise precluding the evaluation of whether dose-escalated SBRT for pancreatic cancer is detrimental, should the study fail to meet its primary endpoint.</p><h3><strong>Resource constraints increase the risk of uninformative trials</strong></h3><p>Design choices that minimize sample size may seem to be a pragmatic response to resource constraints. </p><blockquote><p>However, overestimating effect sizes and inappropriately utilizing one-sided significance testing incur <strong>real risk that a trial will deliver uninformative &#8211; not just negative &#8211; results.</strong> </p></blockquote><p><a href="https://jamanetwork.com/journals/jama/article-abstract/2740057">Uninformative clinical trials</a> waste scarce resources and violate patients&#8217; expectations that trial participation will represent a meaningful contribution to medical science. Avoiding this outcome requires careful scrutiny of a trial&#8217;s effect size projections and approach to significance testing, ideally before enrollment begins.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p>]]></content:encoded></item><item><title><![CDATA[Do we need to be reassured about surrogates? My take in The BMJ.]]></title><description><![CDATA[I was recently invited to comment in The BMJ on the REASSurE framework, developed by Lo and colleagues through a Delphi consensus process to evaluate a single surrogate endpoint against a clinical endpoint.]]></description><link>https://www.theoncologyshot.com/p/do-we-need-to-be-reassured-about</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/do-we-need-to-be-reassured-about</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Wed, 11 Nov 2026 20:35:19 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!CSNR!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>I was recently invited to <a href="https://www.bmj.com/content/395/bmj-2026-101343">comment in </a><em><a href="https://www.bmj.com/content/395/bmj-2026-101343">The BMJ</a></em> on the <a href="https://www.bmj.com/content/394/bmj-2026-100618">REASSurE framework</a>, developed by Lo and colleagues through a Delphi consensus process to evaluate a single surrogate endpoint against a clinical endpoint.</p><p>While I commend the authors for their transparent methods and reporting, I discuss some potential limitations of the <strong>consensus-based approach</strong>, the <strong>limited involvement of patients</strong>, and the implications of incorporating <strong>non-statistical considerations</strong>, such as time savings, disease rarity, and unmet medical needs. Although relevant, these considerations introduce greater subjectivity, potentially allowing more flexibility in decisions about surrogate acceptance. </p><blockquote><p><strong>More broadly, I question whether we need more surrogates, or greater flexibility in accepting them. In oncology, surrogate endpoints are already widely used, despite often limited evidence that they reliably predict survival or quality-of-life benefits. Restricting their use could lead to fewer, but perhaps more meaningful, advances for patients.</strong></p></blockquote><p>Below is the editorial, followed by my conclusion.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!CSNR!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!CSNR!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 424w, https://substackcdn.com/image/fetch/$s_!CSNR!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 848w, https://substackcdn.com/image/fetch/$s_!CSNR!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 1272w, https://substackcdn.com/image/fetch/$s_!CSNR!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!CSNR!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png" width="1456" height="751" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:751,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2087064,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/224502745?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!CSNR!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 424w, https://substackcdn.com/image/fetch/$s_!CSNR!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 848w, https://substackcdn.com/image/fetch/$s_!CSNR!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 1272w, https://substackcdn.com/image/fetch/$s_!CSNR!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa5a683b3-30f4-4d42-a604-f3bce83a9320_2672x1378.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3>The REASSurE framework for evaluating a single surrogate endpoint</h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!VM4a!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!VM4a!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 424w, https://substackcdn.com/image/fetch/$s_!VM4a!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 848w, https://substackcdn.com/image/fetch/$s_!VM4a!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 1272w, https://substackcdn.com/image/fetch/$s_!VM4a!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!VM4a!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png" width="1228" height="844" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/eab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:844,&quot;width&quot;:1228,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:304386,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/224502745?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!VM4a!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 424w, https://substackcdn.com/image/fetch/$s_!VM4a!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 848w, https://substackcdn.com/image/fetch/$s_!VM4a!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 1272w, https://substackcdn.com/image/fetch/$s_!VM4a!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Feab2f808-8b37-4a45-9e81-ef5574580fbb_1228x844.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">from <a href="https://www.bmj.com/content/bmj/395/bmj-2026-101343.full.pdf">Olivier. BMJ, 2026</a>. </figcaption></figure></div><h3>Consensus may come at a cost.</h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!4kSz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!4kSz!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 424w, https://substackcdn.com/image/fetch/$s_!4kSz!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 848w, https://substackcdn.com/image/fetch/$s_!4kSz!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 1272w, https://substackcdn.com/image/fetch/$s_!4kSz!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!4kSz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png" width="1228" height="392" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:392,&quot;width&quot;:1228,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:152282,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/224502745?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!4kSz!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 424w, https://substackcdn.com/image/fetch/$s_!4kSz!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 848w, https://substackcdn.com/image/fetch/$s_!4kSz!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 1272w, https://substackcdn.com/image/fetch/$s_!4kSz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F06b1f919-2ca6-43eb-ba42-3163c4c3d7f1_1228x392.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">from <a href="https://drive.google.com/file/d/1ImsGqoNr6AekzsVPew1vp9tNp-GvCLql/view">Olivier. BMJ, 2026</a>. </figcaption></figure></div><h3>Patient involvement: the too-often missing component.</h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!haM5!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!haM5!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 424w, https://substackcdn.com/image/fetch/$s_!haM5!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 848w, https://substackcdn.com/image/fetch/$s_!haM5!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 1272w, https://substackcdn.com/image/fetch/$s_!haM5!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!haM5!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png" width="1228" height="332" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/d1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:332,&quot;width&quot;:1228,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:152169,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/224502745?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!haM5!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 424w, https://substackcdn.com/image/fetch/$s_!haM5!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 848w, https://substackcdn.com/image/fetch/$s_!haM5!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 1272w, https://substackcdn.com/image/fetch/$s_!haM5!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd1d43fd0-99c8-40d8-85d9-db0b28b43b4c_1228x332.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">from <a href="https://drive.google.com/file/d/1ImsGqoNr6AekzsVPew1vp9tNp-GvCLql/view">Olivier. BMJ, 2026</a>. </figcaption></figure></div><h3>Non-statistical factors matter&#8230; yet they introduce subjectivity.</h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!uLJB!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!uLJB!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 424w, https://substackcdn.com/image/fetch/$s_!uLJB!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 848w, https://substackcdn.com/image/fetch/$s_!uLJB!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 1272w, https://substackcdn.com/image/fetch/$s_!uLJB!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!uLJB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png" width="1228" height="492" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:492,&quot;width&quot;:1228,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:218366,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/224502745?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!uLJB!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 424w, https://substackcdn.com/image/fetch/$s_!uLJB!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 848w, https://substackcdn.com/image/fetch/$s_!uLJB!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 1272w, https://substackcdn.com/image/fetch/$s_!uLJB!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F950dde1c-1cec-4536-a96e-adb3e27e7ebc_1228x492.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">from <a href="https://drive.google.com/file/d/1ImsGqoNr6AekzsVPew1vp9tNp-GvCLql/view">Olivier. BMJ, 2026</a>. </figcaption></figure></div><h3>But do we really need more surrogates?</h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!HxSG!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!HxSG!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 424w, https://substackcdn.com/image/fetch/$s_!HxSG!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 848w, https://substackcdn.com/image/fetch/$s_!HxSG!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 1272w, https://substackcdn.com/image/fetch/$s_!HxSG!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!HxSG!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png" width="1228" height="568" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:568,&quot;width&quot;:1228,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:219979,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/224502745?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!HxSG!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 424w, https://substackcdn.com/image/fetch/$s_!HxSG!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 848w, https://substackcdn.com/image/fetch/$s_!HxSG!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 1272w, https://substackcdn.com/image/fetch/$s_!HxSG!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13331952-444f-4028-a2a8-5b6a560b1591_1228x568.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">from <a href="https://drive.google.com/file/d/1ImsGqoNr6AekzsVPew1vp9tNp-GvCLql/view">Olivier. BMJ, 2026</a>. </figcaption></figure></div><h3>My conclusion</h3><blockquote><p><strong>&#8220;REASSurE is valuable because it makes the judgments surrounding surrogate evaluation more explicit. Whether the framework will be widely adopted and ultimately benefit patients remains to be seen.&#8221;</strong></p></blockquote><p>Here is the link for the <a href="https://drive.google.com/file/d/1ImsGqoNr6AekzsVPew1vp9tNp-GvCLql/view">full article</a> (with references). </p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p><p><br><br></p>]]></content:encoded></item><item><title><![CDATA[Currency of Influence in Oncology]]></title><description><![CDATA[Influencing prescribing decisions does not require large payments.]]></description><link>https://www.theoncologyshot.com/p/currency-of-influence-in-oncology</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/currency-of-influence-in-oncology</guid><dc:creator><![CDATA[Saroj Niraula]]></dc:creator><pubDate>Sat, 31 Oct 2026 17:31:20 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!tW4J!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><em>In today&#8217;s guest post, it&#8217;s my great pleasure to welcome Saroj Niraula, who recently commented, together with Ian Tannock, on a JCO study by Aaron Mitchell and colleagues showing how payments as small as $45 are associated with prescribing decisions involving cancer drugs. And anti-cancer drugs can cost tens of thousands of dollars per month! Timoth&#233;e</em></p><div><hr></div><p><strong>Ask oncologists whether they would change a cancer prescription because a pharmaceutical company bought them dinner. Almost everyone would say no. Most would probably even find the question insulting. Now consider what researchers found when they examined actual prescribing behaviour.</strong></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!tW4J!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!tW4J!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 424w, https://substackcdn.com/image/fetch/$s_!tW4J!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 848w, https://substackcdn.com/image/fetch/$s_!tW4J!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 1272w, https://substackcdn.com/image/fetch/$s_!tW4J!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!tW4J!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png" width="1456" height="753" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:753,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2915472,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/221532618?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!tW4J!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 424w, https://substackcdn.com/image/fetch/$s_!tW4J!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 848w, https://substackcdn.com/image/fetch/$s_!tW4J!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 1272w, https://substackcdn.com/image/fetch/$s_!tW4J!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44bb0fac-b5b7-4562-a6f3-3de23abc5fc7_2676x1384.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>In a recent <em><strong><a href="https://doi.org/10.1200/JCO-26-00785">Journal of Clinical Oncology</a></strong></em> study, Aaron Mitchell and colleagues found that oncologists who received payments from pharmaceutical companies were more likely to prescribe treatments marketed by those companies. The association was apparent whether the promoted treatments were preferred or nonpreferred under clinical guidelines. It also became stronger as payments increased (see figure 1).</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!zvEY!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!zvEY!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 424w, https://substackcdn.com/image/fetch/$s_!zvEY!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 848w, https://substackcdn.com/image/fetch/$s_!zvEY!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 1272w, https://substackcdn.com/image/fetch/$s_!zvEY!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!zvEY!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png" width="1456" height="1378" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/b1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1378,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:459214,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/221532618?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!zvEY!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 424w, https://substackcdn.com/image/fetch/$s_!zvEY!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 848w, https://substackcdn.com/image/fetch/$s_!zvEY!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 1272w, https://substackcdn.com/image/fetch/$s_!zvEY!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb1094086-1d53-4fdd-b190-9db795c7eddb_1602x1516.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Figure 1 from <em><a href="https://ascopubs.org/doi/full/10.1200/JCO-26-00785">Mitchell et al. Journal Clinical Oncology 2026</a></em></figcaption></figure></div><p>The median payments were just $45 and $61, respectively for guideline preferred and guideline nonpreferred treatments.</p><blockquote><p>Think about that: we are talking about highly trained physicians making decisions about treatments that can cost tens of thousands of dollars every month. Their prescribing patterns were associated with financial relationships involving amounts that most oncologists would have no issue comfortably spending on lunch or dinner.</p></blockquote><p>We discussed these findings in an accompanying <em><strong><a href="https://doi.org/10.1200/JCO-26-01789">Journal of Clinical Oncology</a></strong></em> editorial which I will summarize here.</p><h3><strong>Pharma understands human behaviour rather well</strong></h3><p>Pharmaceutical companies spend extraordinary amounts of money promoting their products to physicians. A <a href="https://doi.org/10.1001/jama.2018.19320">JAMA analysis</a> estimated that US pharmaceutical companies spent $20.3 billion on marketing to healthcare professionals in 2016, including nearly $1 billion in direct payments for nonresearch activities.</p><p>There is evidence that this spending affects prescribing. In a <a href="https://jamanetwork.com/journals/jama/fullarticle/2623607">2017 JAMA study</a>, researchers examined what happened when 19 academic medical centres restricted access to pharmaceutical sales representatives. Prescribing shifted modestly away from promoted drugs following those restrictions.</p><blockquote><p><strong>Such findings are especially revealing: by simply reducing exposure to marketing, prescribing behaviour changed.</strong></p></blockquote><h3><strong>How does marketing work on people who sincerely believe they cannot be influenced?</strong></h3><p>We tend to imagine that influencing a physician requires a substantial payment in exchange for a favour. Pharmaceutical promotion can operate far more subtly.</p><p>Imagine encountering the same drug repeatedly. You hear about it during a sponsored presentation. The venue is perfect. The message comes from well-dressed, eloquent and engaging speakers. Its trial results are discussed by a respected colleague. You see the drug again and again in a company-supported educational programme. Over time, the name becomes familiar. When you next face a relevant clinical decision, it comes readily to mind.</p><p>There is nothing mysterious about this. <strong>Familiarity influences human judgement.</strong> Repeated exposure can make information easier to recall and more comfortable to act upon. It is particularly relevant in oncology, where <strong>several treatment options may be considered reasonable despite limited comparative evidence</strong>. </p><blockquote><p><strong>Pharma does not need a physician to abandon their professional ethics. A modest shift in prescribing probability, multiplied across thousands of decisions can be commercially valuable. And the physician can remain completely convinced that the choice was their own.</strong></p></blockquote><h3><strong>There is a reward more intoxicating than an honorarium</strong></h3><p>Money is only one part of the story. For an academic oncologist, recognition alone can be a powerful incentive. An invitation to speak at an international conference carries considerable professional value. So does being approached by a major company as an expert in a particular disease. Pharmaceutical companies can also offer access to research opportunities that help establish academic prominence. That prominence may lead to greater influence over how a treatment is understood and used.</p><blockquote><p><strong>Not every industry invitation is an attempt to manipulate a physician, nor does recognition automatically compromise judgement. The concern is what happens when academic success becomes closely connected to the commercial success of a treatment.</strong></p></blockquote><p>The same can occur in the absence of financial relationships, and we have argued that <strong><a href="https://doi.org/10.1038/s41571-025-01073-3">nonfinancial conflicts of interest</a> deserve greater attention</strong>. For instance, a clinician who has invested years developing a drug may become deeply committed to its clinical value, even in the absence of financial motivations. The more publicly that position has been defended, the harder it may become to reconsider.</p><h3><strong>The ultimate prize: a physician who influences other physicians</strong></h3><p>The implications become more serious when influential experts, heads of departments or disease-sites, help determine how the rest of us practise oncology.</p><p>In a recent <em><strong><a href="https://doi.org/10.1016/j.ejca.2026.116844">European Journal of Cancer</a></strong></em> article, we argued that conflicts become especially consequential when physicians are given the authority to interpret evidence for others. We need to be much more discerning about whom we choose to exercise that authority.</p><p>Consider a new cancer drug that improves progression-free survival by a few months, with uncertain effects on survival, high cost, and possible compromise in quality of life due to toxicities. A respected oncologist presents the result as a major advance. The treatment features prominently in educational sessions. Eventually, it becomes part of routine clinical practice.</p><blockquote><p><strong>Who decided that the magnitude of benefit justified such enthusiasm? Often, the answer lies in &#8220;expert interpretation&#8221;. And some of those experts have substantial financial relationships with the companies whose products they evaluate.</strong></p></blockquote><h3><strong>Disclosure has become a comfortable ritual</strong></h3><p>Anyone who regularly attends oncology conferences knows the familiar disclosure slide. Sometimes it contains so many pharmaceutical company names that reading them would consume the entire allotted time. The speaker displays it briefly and moves on to discuss the clinical evidence. </p><blockquote><p><strong>Disclosure is necessary, of course. But declaring an influence does nothing to eliminate it. We have somehow come to regard this as satisfactory conflict-of-interest management. But what protection does the audience actually receive?</strong></p></blockquote><p>Would patients be reassured to learn that the person recommending their treatment has financial relationships with its manufacturer, <strong>provided these are listed on a slide?</strong></p><h3><strong>We should stop confusing marketing with scientific collaboration</strong></h3><p>Whenever restrictions on industry payments are proposed, someone inevitably warns that pharmaceutical innovation depends on collaboration with physicians.</p><p>Of course it does. </p><blockquote><p><strong>Academic oncologists have an important role in developing new treatments and improving clinical trials. Industry-funded research has delivered extraordinary advances in cancer care. We should encourage productive collaborations that generate reliable evidence and improve outcomes for patients.</strong> </p></blockquote><p>But it is difficult to see why developing a better cancer treatment requires the same physician to participate in promotional speaker programmes. We should be willing to acknowledge that distinction.</p><p>Academic societies should place meaningful restrictions on personal promotional payments, particularly for members who develop guidelines and oversee professional education. Journals should be more selective about commissioning interpretive articles from authors with relevant financial relationships. Institutions should provide independent education rather than relying on companies to organise it.</p><p>These are practical steps. They would preserve the valuable contributions of industry to drug development while reducing avoidable commercial influence over clinical decisions.</p><p><strong>This is the key figure from our editorial, where we clearly outline the differences between collaration and marketing.</strong> </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!Ew9p!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Ew9p!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 424w, https://substackcdn.com/image/fetch/$s_!Ew9p!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 848w, https://substackcdn.com/image/fetch/$s_!Ew9p!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 1272w, https://substackcdn.com/image/fetch/$s_!Ew9p!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!Ew9p!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png" width="1456" height="953" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/debeb8e3-9957-410f-aad6-64f86175920a_1466x960.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:953,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:570649,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/221532618?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!Ew9p!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 424w, https://substackcdn.com/image/fetch/$s_!Ew9p!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 848w, https://substackcdn.com/image/fetch/$s_!Ew9p!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 1272w, https://substackcdn.com/image/fetch/$s_!Ew9p!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdebeb8e3-9957-410f-aad6-64f86175920a_1466x960.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>Who pays the price?</strong></h3><p>Perhaps the most uncomfortable aspect of all this is that the patient is absent from these arrangements.</p><p>The company pays for a meal or sponsors an educational event. An influential physician receives professional recognition. A guideline panel recommends a treatment. The oncologist in the clinic makes a prescription. <strong>The patient only sees a trusted professional offering medical advice.</strong></p><p>Cancer patients already face enough uncertainty. They should be able to trust that the recommendation they receive has been insulated, as far as reasonably possible, from commercial promotion.</p><div><hr></div><p>I do not doubt the sincerity of oncologists who believe they are immune to such influence. That confidence is precisely what makes the problem difficult.</p><p><strong>However, as shown repeatedly, financial relationships are associated with prescribing behaviour. Similarly, we have evidence that restricting promotional exposure can change prescribing. How much more evidence should we require before reconsidering arrangements that offer no indispensable benefit to patients?</strong></p><blockquote><p>The next time a pharmaceutical company offers us a dinner, a speaking invitation, or a promotional advisory role, we should ask ourselves two questions: <strong>Why is the company making this offer? And what makes us so confident that we cannot be influenced?</strong></p></blockquote><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p>]]></content:encoded></item><item><title><![CDATA[My MD-Anderson Cancer Center Madrid Hospiten Talk]]></title><description><![CDATA[&#8220;How to Read Clinical Trial Reports: A Focus on Breast Cancer.&#8221;]]></description><link>https://www.theoncologyshot.com/p/my-md-anderson-cancer-center-madrid</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/my-md-anderson-cancer-center-madrid</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Thu, 29 Oct 2026 07:02:04 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/222465674/e3ae6497e03077f19fef8d1559c1d6af.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<p>On October 22, 2026, just before the start of the ESMO Congress, I had the great honor and pleasure of giving a lecture at MD Anderson Cancer Center Madrid &#8211; Hospiten.</p><p>I also had the pleasure of sharing the stage with <a href="https://gufaculty360.georgetown.edu/s/contact/00336000014TnABAA0/sandra-swain">Prof. Sandra M. Swain</a>, who gave a fantastic lecture on adjuvant treatment in breast cancer.</p><p>Here is my talk, entitled <strong>&#8220;How to Read Clinical Trial Reports: A Focus on Breast Cancer,&#8221;</strong> with timestamps if needed:</p><ul><li><p><strong>1:01</strong> &#8211; The control arm</p></li><li><p><strong>6:55</strong> &#8211; Suboptimal post-protocol care: monarchE and NATALEE</p></li><li><p><strong>18:04</strong> &#8211; Interpreting PFS: the PATINA trial</p></li><li><p><strong>22:59</strong> &#8211; The basics of Kaplan&#8211;Meier, Part 1</p></li><li><p><strong>25:08</strong> &#8211; Introduction to informative censoring: the BREAKING-ICE App and PATINA</p></li><li><p><strong>34:38</strong> &#8211; Informative censoring in the adjuvant setting? NATALEE and &#8220;informative censoring areas&#8221;</p></li><li><p><strong>37:47</strong> &#8211; Conclusions</p></li></ul><p>Thanks again to <a href="https://mdandersonhospiten.es/Curriculum/dra-laura-garcia-estevez">Dr Laura Garc&#237;a Est&#233;vez</a>, Head of the Oncology Unit, and <a href="https://mdandersonhospiten.es/en/curriculum/dr-santiago-gonzalez-moreno">Dr. Santiago Gonz&#225;lez Moreno</a>, Medical Director of MD Anderson Cancer Center Madrid &#8211; Hospiten, for their kind invitation and the great discussions!</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!3VJC!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!3VJC!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 424w, https://substackcdn.com/image/fetch/$s_!3VJC!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 848w, https://substackcdn.com/image/fetch/$s_!3VJC!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!3VJC!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!3VJC!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg" width="1106" height="1280" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1280,&quot;width&quot;:1106,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:362711,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/jpeg&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/222465674?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!3VJC!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 424w, https://substackcdn.com/image/fetch/$s_!3VJC!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 848w, https://substackcdn.com/image/fetch/$s_!3VJC!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!3VJC!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F13967781-7746-41b2-8d60-abfffa6461a3_1106x1280.jpeg 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-tqxFUX" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-tqxFUX" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Santiago Gonz&#225;lez-Moreno, Sandra M. Swain, myself, and Laura Garc&#237;a Est&#233;vez</figcaption></figure></div><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p><br></p><p></p><p><br></p>]]></content:encoded></item><item><title><![CDATA[Not One, but Two Papers! What Daraxonrasib’s Recent Results Mean for Ongoing and Future Trials]]></title><description><![CDATA[Today I want to highlight two recent works we published about daraxonrasib and emerging RAS(ON) inhibitors in pancreatic cancer.]]></description><link>https://www.theoncologyshot.com/p/not-one-but-two-papers-what-daraxonrasibs</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/not-one-but-two-papers-what-daraxonrasibs</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Wed, 28 Oct 2026 13:24:02 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!r18g!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Today I want to highlight two recent works we published about daraxonrasib and emerging RAS(ON) inhibitors in pancreatic cancer. </p><p>As a brief recap (if needed): the RASolute 302 trial marked a major advance, with daraxonrasib nearly doubling median overall survival <em>versus</em> chemotherapy in the second-line metastatic setting of patients with pancreatic cancer (13.2 vs 6.7 months; HR 0.40). </p><p><strong>The benefit seen in RASolute 302 is beyond dispute, and patients and families are naturally eagerly awaiting access to the drug.</strong> </p><blockquote><p><strong>In both papers, we discuss potential limitations of the current evidence, and implications for ongoing and future trials of both systemic therapies and radiotherapy.</strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!r18g!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!r18g!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 424w, https://substackcdn.com/image/fetch/$s_!r18g!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 848w, https://substackcdn.com/image/fetch/$s_!r18g!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 1272w, https://substackcdn.com/image/fetch/$s_!r18g!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!r18g!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png" width="1456" height="750" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:750,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:434108,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/222326430?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!r18g!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 424w, https://substackcdn.com/image/fetch/$s_!r18g!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 848w, https://substackcdn.com/image/fetch/$s_!r18g!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 1272w, https://substackcdn.com/image/fetch/$s_!r18g!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F44d40823-6740-4ce6-9568-8c0cc63b923c_2680x1380.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>1 - &#8220;Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence&#8221;, with Sruthi Ranganathan, in the </strong><em><strong>Journal of Clinical Oncology</strong></em></h3><p>In this paper, we first highlight that the survival benefit seen in RASolute 302, although undeniable, may be overestimated due to short follow-up and potentially informative censoring.</p><p>We then discuss the risks of expanding access beyond the current evidence. Importantly, the paper was written <strong>before the FDA approved</strong> daraxonrasib with a label extending the indication to patients <strong>&#8220;not candidates for multiagent systemic therapy&#8221;</strong>, a decision that only reinforces the concerns we raised (see also the <a href="https://www.theoncologyshot.com/p/daraxonrasib-is-fda-approved-both">post here</a>).</p><p>We also discuss the <strong>suboptimal chemotherapy-only control arm</strong> in the ongoing first-line <strong>RASolute 303</strong> trial, which may lead to excess dropout and potentially bias the comparison.</p><p>We <strong>call for the protocol to be amended</strong> to include a triplet chemotherapy regimen as a control option and argue that crossover to daraxonrasib should be mandatory.</p><p>We also provide a table with <strong>key information to support informed decision-making</strong> when considering enrollment in RASolute 303.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!s9Je!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!s9Je!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 424w, https://substackcdn.com/image/fetch/$s_!s9Je!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 848w, https://substackcdn.com/image/fetch/$s_!s9Je!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 1272w, https://substackcdn.com/image/fetch/$s_!s9Je!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!s9Je!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png" width="944" height="1096" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/b7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1096,&quot;width&quot;:944,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:260523,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/222326430?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!s9Je!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 424w, https://substackcdn.com/image/fetch/$s_!s9Je!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 848w, https://substackcdn.com/image/fetch/$s_!s9Je!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 1272w, https://substackcdn.com/image/fetch/$s_!s9Je!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb7c4a6b5-2261-499f-9621-696abbb66022_944x1096.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Open-access link of this first paper is here : <strong>&#8220;<a href="https://ascopubs.org/doi/10.1200/JCO-26-01457">Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence</a>&#8221;</strong></p><h3><strong>2 - &#8220;A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials&#8221;, with </strong><span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Susannah Ellsworth&quot;,&quot;id&quot;:6793799,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:null,&quot;uuid&quot;:&quot;c1fd12a0-f83f-40aa-849f-f931fbe592c4&quot;}" data-component-name="MentionToDOM"></span>, in the<strong> </strong><em><strong>European Journal of Cancer</strong></em></h3><p>In this second paper, we revisit decades of radiotherapy trials in pancreatic cancer and how evolving systemic therapies have complicated their interpretation.</p><p>With RAS-targeted therapies potentially transforming treatment paradigms, <strong>these methodological challenges are becoming even more critical for ongoing trials</strong> (such as GI-011) and <strong>future radiotherapy trials</strong>.</p><p>The paper offers several other insights worth exploring!</p><p>Open-access link of this second paper is here: <strong>&#8220;<a href="https://www.ejcancer.com/article/S0959-8049(26)01572-8/fulltext">A new era in anti-RAS therapy: Unique challenges and opportunities for radiotherapy clinical trials</a>&#8221;</strong></p><p>Many thanks to both my co-authors for their great work on these two papers!</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p>]]></content:encoded></item><item><title><![CDATA[What to look for in NATALEE’s 6-year overall survival results: post-protocol care.]]></title><description><![CDATA[An excerpt from my MD Anderson Cancer Center Madrid talk.]]></description><link>https://www.theoncologyshot.com/p/what-to-look-for-in-natalees-6-year</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/what-to-look-for-in-natalees-6-year</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Thu, 22 Oct 2026 21:03:24 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/221695383/3ef37ac5b39ced0a2ff31c9708718e03.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<p>Today, 22 October 2026, I was honored to be invited to give a lecture at <a href="https://mdandersonhospiten.es/">MD Anderson Cancer Center Madrid &#8211; Hospiten</a>.</p><p>During my talk, I discussed the upcoming 6-year overall survival results of the NATALEE trial, which will be presented tomorrow, 23 October, at ESMO 2026 in Madrid.</p><p>In this excerpt from the lecture, I explain why your focus tomorrow should be on&#8230; <strong>post-protocol care data!</strong></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p>]]></content:encoded></item><item><title><![CDATA[The forgotten question: does each drug actually matter?]]></title><description><![CDATA[Most of the time, we never get much further than the back cover of a book.]]></description><link>https://www.theoncologyshot.com/p/the-forgotten-question-does-each</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/the-forgotten-question-does-each</guid><dc:creator><![CDATA[Sahar van Waalwijk]]></dc:creator><pubDate>Fri, 09 Oct 2026 06:47:12 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!hr5P!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Most of the time, we never get much further than the back cover of a book. Life is busy, and there are simply too many books to read. The same goes for scientific papers. We often stop at the abstract. There are simply too many publications and too little time to read them all. But every now and then, it&#8217;s fun to go through the whole paper and read it as a clinical assessor.</p><p>If you decide to read a paper, and you&#8217;re the kind of person who enjoys detective stories, I challenge you to pick a paper on a combination of drugs. Look at the trial design, the patient population, the subgroup analyses, the control arm, and the quality-of-life data.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!hr5P!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!hr5P!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 424w, https://substackcdn.com/image/fetch/$s_!hr5P!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 848w, https://substackcdn.com/image/fetch/$s_!hr5P!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 1272w, https://substackcdn.com/image/fetch/$s_!hr5P!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!hr5P!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png" width="908" height="606" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a2529f22-798a-4036-b901-23b82818c074_908x606.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:606,&quot;width&quot;:908,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1207426,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/219419170?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!hr5P!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 424w, https://substackcdn.com/image/fetch/$s_!hr5P!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 848w, https://substackcdn.com/image/fetch/$s_!hr5P!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 1272w, https://substackcdn.com/image/fetch/$s_!hr5P!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa2529f22-798a-4036-b901-23b82818c074_908x606.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>Why does contribution of component matters?</strong></h3><p>In oncology, we are seeing more and more combination therapies, which is not surprising given the heterogeneity of cancer. But perhaps one of the most overlooked questions is what regulators call &#8220;contribution of component.&#8221;</p><blockquote><p><strong>If Drug A and Drug B are given together, how do we know Drug B is actually adding value?</strong></p></blockquote><p>This is not just an academic question. It is even a moral one. You are exposing patients to additional toxicity. And in publicly funded healthcare systems, you are substantially increasing healthcare costs. Surely that should be justified.</p><p>Yet without the right trial design, determining whether each drug truly contributes to the benefit of the combination remains surprisingly difficult.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!BtMb!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!BtMb!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 424w, https://substackcdn.com/image/fetch/$s_!BtMb!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 848w, https://substackcdn.com/image/fetch/$s_!BtMb!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 1272w, https://substackcdn.com/image/fetch/$s_!BtMb!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!BtMb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png" width="908" height="606" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/bb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:606,&quot;width&quot;:908,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1078129,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/219419170?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!BtMb!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 424w, https://substackcdn.com/image/fetch/$s_!BtMb!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 848w, https://substackcdn.com/image/fetch/$s_!BtMb!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 1272w, https://substackcdn.com/image/fetch/$s_!BtMb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fbb392130-95a2-4e40-ad35-9f2616497c7f_908x606.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>You need to scrutinise the trial design</strong></h3><p>In our recent paper in <a href="https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djag343/8834116?redirectedFrom=fulltext#no-access-message">the JNCI</a>, we discuss trial designs for combination therapies (see Table 1). The design is not only important for understanding how much each drug contributes to the overall effect, but also for determining which biological subgroup benefits most from the therapy.</p><p>Unfortunately, trials designed by drug developers rarely answer this question, as answering it is often not aligned with their commercial interests. Instead, studies are typically conducted in broad patient populations.</p><p>When a trial is positive overall, there is often pressure to extend the conclusions to everyone enrolled. Yet a positive trial can mask an uncomfortable reality: the observed effect may be driven largely by a single subgroup. The problem is that subgroup analyses are often underpowered and difficult to interpret. As a result, we may end up treating everyone, even though only a subset of patients truly benefits.</p><h3><strong>Table 1. Trial designs for combination therapies.</strong></h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!b0_C!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!b0_C!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 424w, https://substackcdn.com/image/fetch/$s_!b0_C!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 848w, https://substackcdn.com/image/fetch/$s_!b0_C!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 1272w, https://substackcdn.com/image/fetch/$s_!b0_C!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!b0_C!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png" width="742" height="528" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:528,&quot;width&quot;:742,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!b0_C!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 424w, https://substackcdn.com/image/fetch/$s_!b0_C!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 848w, https://substackcdn.com/image/fetch/$s_!b0_C!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 1272w, https://substackcdn.com/image/fetch/$s_!b0_C!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F82a85cd8-7d83-4f5e-ac9e-43b046d9f9ca_742x528.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>Are the biological subgroups prospectively defined and tested separately?</strong></h3><p>The best trial designs prospectively define and test biologically distinct patient groups separately. This may sound more complicated, and the common perception is that it requires larger trials and more patients. Ironically, the opposite can be true.</p><p>The MAGNITUDE trial in prostate cancer is a good example. <a href="https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(25)00660-1/fulltext">By prospectively separating patients based on biological characteristics, the study was able to provide much clearer answers about who actually benefits from treatment</a>. At the same time, it enrolled fewer patients than some of the seemingly simpler all-comer trials. In other words, a better question can sometimes require fewer patients, not more.</p><h3><strong>What happens after the trial?</strong></h3><p>Another thing that is often overlooked is what happens after the trial. If a combination simply brings first-line and second-line treatments together upfront, then what matters is not only whether the combination is better than the control arm during the trial. Patients in the control arm should also have access to the second-line therapy after progression. In this situation, the real comparison is not the combination versus a single drug. It is the combination versus sequential therapy.</p><p>In our recent JNCI paper, we provide a simple set of questions to guide your assessment. Take a combination trial, keep Table 2 next to you, and work your way through the paper.</p><blockquote><p><strong>You may find that the most interesting part of the paper is not whether the trial was positive, overall. It&#8217;s whether each drug actually contributed to the combination, whether the endpoints are meaningful, whether the assessments were properly blinded to avoid bias, whether the added toxicity and costs are justified by the magnitude of benefit, and whether the trial design tells us who truly benefits from the therapy.</strong></p></blockquote><h3><strong>Table 2. Key considerations in oncology combination therapy trials</strong></h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!mBjm!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!mBjm!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 424w, https://substackcdn.com/image/fetch/$s_!mBjm!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 848w, https://substackcdn.com/image/fetch/$s_!mBjm!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 1272w, https://substackcdn.com/image/fetch/$s_!mBjm!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!mBjm!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png" width="748" height="753" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:753,&quot;width&quot;:748,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!mBjm!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 424w, https://substackcdn.com/image/fetch/$s_!mBjm!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 848w, https://substackcdn.com/image/fetch/$s_!mBjm!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 1272w, https://substackcdn.com/image/fetch/$s_!mBjm!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c783fc5-464d-47a2-a65e-09419a0de3ae_748x753.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Read the full article for more insights, openly available <a href="https://drive.google.com/file/d/15ijA0efpQJ4GVuYK7uqjQw8-r5zb3Wxd/view?usp=drive_link">here</a>!</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[My Fribourg talk, in French! Statistics in Oncology in Practice]]></title><description><![CDATA[I was invited on 18th September to give a lecture at Fribourg Cantonal Hospital on Statistics in Oncology in Practice. Thanks to Prof Alessandra Curioni Fontecedro, Dr V&#233;r&#232;ne Dougoud, and the team for the invitation and warm welcome.]]></description><link>https://www.theoncologyshot.com/p/my-fribourg-talk-in-french-statistics</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/my-fribourg-talk-in-french-statistics</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Sat, 19 Sep 2026 20:15:34 GMT</pubDate><enclosure url="https://api.substack.com/feed/podcast/216353081/a986ece5b54c3975c928312de3642d08.mp3" length="0" type="audio/mpeg"/><content:encoded><![CDATA[<p>I was invited on 18th September to give a lecture at Fribourg Cantonal Hospital on <strong>Statistics in Oncology in Practice</strong>. Thanks to <a href="https://www.linkedin.com/in/curioni-alessandra/">Prof Alessandra Curioni Fontecedro</a>, Dr <a href="https://www.h-fr.ch/annuaire/dr-verene-dougoud">V&#233;r&#232;ne Dougoud</a>, and the team for the invitation and warm welcome. </p><p>The talk aims to be highly practical: Kaplan&#8211;Meier plots, informative censoring, and more, illustrated with recent trials including CONTACT-02, LUNAR, PANOVA, RASolute 303 (daraxonrasib) and others!</p><p>A special acknowledgment to <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Vinay Prasad MD MPH&quot;,&quot;id&quot;:21798998,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:&quot;https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8d9b3de5-2e57-4d32-a0d4-99f8431caa20_8688x5792.jpeg&quot;,&quot;uuid&quot;:&quot;30ff5af2-7e2f-4b08-b542-7efed0626ba9&quot;}" data-component-name="MentionToDOM"></span>, whose work and our collaborations have greatly influenced this talk. </p><p>Hope you enjoy it!</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div>]]></content:encoded></item><item><title><![CDATA[A Cultural Gap: How Many Patients With Metastatic Pancreatic Cancer Do Not Start Systemic Therapy? ]]></title><description><![CDATA[Different cultural approches between the Netherlands and the US.]]></description><link>https://www.theoncologyshot.com/p/a-cultural-gap-how-many-patients</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/a-cultural-gap-how-many-patients</guid><pubDate>Sun, 06 Sep 2026 15:21:05 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!N5Xb!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>My attention was recently drawn to two real-world studies.</p><p>The first is coming from the Netherlands, published in the <em>European Journal of Cancer</em>. The full article is available <strong><a href="https://www.sciencedirect.com/science/article/pii/S0959804926007240">here</a></strong>. In their work, Broekman et al. wanted to identify factors associated with <strong>not receiving systemic therapy</strong> in patients diagnosed with metastatic pancreatic adenocarcinoma in the Netherlands between 2015 and 2023.</p><blockquote><p><strong>The most striking finding : 72% of patients did not receive any systemic therapy, mostly based on patient and family preference (39%). </strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!N5Xb!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!N5Xb!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 424w, https://substackcdn.com/image/fetch/$s_!N5Xb!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 848w, https://substackcdn.com/image/fetch/$s_!N5Xb!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 1272w, https://substackcdn.com/image/fetch/$s_!N5Xb!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!N5Xb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png" width="1456" height="752" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:752,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2971418,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/214396518?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!N5Xb!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 424w, https://substackcdn.com/image/fetch/$s_!N5Xb!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 848w, https://substackcdn.com/image/fetch/$s_!N5Xb!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 1272w, https://substackcdn.com/image/fetch/$s_!N5Xb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7c92afd8-d184-4c9d-b507-deabf02147ec_2686x1388.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Other results were nicely summarized by <a href="https://x.com/OncoThor/status/2093897525593821336?s=20">Thor Halfdanarson</a>, a medical oncologist at Mayo Clinic: </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!p6wT!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!p6wT!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 424w, https://substackcdn.com/image/fetch/$s_!p6wT!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 848w, https://substackcdn.com/image/fetch/$s_!p6wT!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 1272w, https://substackcdn.com/image/fetch/$s_!p6wT!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!p6wT!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png" width="1418" height="920" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/f0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:920,&quot;width&quot;:1418,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:329094,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/209775893?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!p6wT!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 424w, https://substackcdn.com/image/fetch/$s_!p6wT!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 848w, https://substackcdn.com/image/fetch/$s_!p6wT!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 1272w, https://substackcdn.com/image/fetch/$s_!p6wT!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Ff0836c16-da26-41a3-94d7-93e5c2ce360a_1418x920.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3>Reactions</h3><p>The reactions on social media mostly highlighted that such pattern was the opposite of in the USA.</p><blockquote><p>Thor Halfdanarson : &#8220;Very much unlike my experience as an oncologist in the U.S. <strong>where most patients I see want systemic therapy.</strong>&#8221; and the following conversation with a patient / advocate, <a href="https://x.com/JudsonKimmel1/status/2094086763316686976?s=20">Jud Kimmel</a>:</p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!Et0h!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Et0h!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 424w, https://substackcdn.com/image/fetch/$s_!Et0h!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 848w, https://substackcdn.com/image/fetch/$s_!Et0h!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 1272w, https://substackcdn.com/image/fetch/$s_!Et0h!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!Et0h!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png" width="1178" height="860" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/5229627d-6264-4188-80fc-723128181dac_1178x860.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:860,&quot;width&quot;:1178,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:251071,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/214396518?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!Et0h!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 424w, https://substackcdn.com/image/fetch/$s_!Et0h!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 848w, https://substackcdn.com/image/fetch/$s_!Et0h!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 1272w, https://substackcdn.com/image/fetch/$s_!Et0h!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5229627d-6264-4188-80fc-723128181dac_1178x860.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Personal experiences, coming from an oncologist and a patient / advocate, are highly valuable. But caution is needed before drawing broad conclusions. In many places, patients who decide not to undergo chemotherapy may never meet a GI oncologist, whose clinical experience is therefore based on an already selected group of patients. Similarly, a patient advocate may have more contact with patients who are highly proactive in managing their disease and treatment than with those who choose not to pursue that path. For these reasons, it is important to look the actual data.</p><h3>Flatiron Health US Data</h3><p>The second report that caught my attention was also published recently, where <a href="https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1844261/full">Fuldeore at al.</a> conducted a comparable study in US patients diagnosed between 2019 and 2024. In short, they found an opposite pattern with a minority of 33% of patients not receiving systemic therapy, confirming the thoughts expressed on social media. </p><h3>Survival benefit facing patient&#8217;s preference</h3><p>Systemic therapy can prolong survival in metastatic pancreatic cancer, and for many patients this additional time is highly valuable. But survival is not the only outcome that matters.</p><p>Puting aside the many limitations potentially affecting quality of life results, even when a study shows preserved or improved &#8220;quality of life,&#8221; this does not necessarly capture everything patients may value. Quality-of-life questionnaires may not fully reflect the wish to avoid treatment altogether, preserve a sense of normality, reduce hospital visits, remain independent, or avoid the possibility of spending precious <strong><a href="https://www.sciencedirect.com/science/article/pii/S221353832200042X">time</a></strong> with treatment-related toxicity.</p><p>As oncologists, we should therefore be cautious not to judge these choices. One patient may accept substantial toxicity for a chance of living longer; another may prioritize comfort, autonomy, or time-free from medical treatment. Both choices can be reasonable.</p><blockquote><p>These data challenge an implicit assumption in oncology: that more life is necessarily better. <strong>Living longer is not always the same as living better, and &#8220;better&#8221; can only be defined by the patient.</strong></p></blockquote><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[“Chemo‑free” is not always better: the FDA withdrawal of adagrasib in colorectal cancer]]></title><description><![CDATA[We have all heard the powerful marketing phrases &#8220;chemo-free&#8221; and &#8220;targeted therapy.&#8221; They sound modern, precise, and less toxic.]]></description><link>https://www.theoncologyshot.com/p/chemofree-is-not-always-better-the</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/chemofree-is-not-always-better-the</guid><dc:creator><![CDATA[Sahar van Waalwijk]]></dc:creator><pubDate>Fri, 04 Sep 2026 19:39:11 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!9YKm!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p><span>We have all heard the powerful marketing phrases </span><strong><span>&#8220;chemo-free&#8221; and &#8220;targeted therapy.&#8221;</span></strong><span> They sound modern, precise, and less toxic. Regulators are willing to grant accelerated or conditional approvals on the basis of response rates for such therapies. Clinicians are relieved to have seemingly better news for their patients. </span></p><blockquote><p><strong><span>After all, who looks forward to getting chemotherapy? </span></strong></p></blockquote><p><span>And payers face pressure to reimburse these apparently superior treatment options.</span></p><p><span>Yet, despite how modern, gentle, and sophisticated terms such as &#8220;chemo-free&#8221; and &#8220;targeted therapy&#8221; may sound, they do not automatically mean better outcomes or safer treatment.</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!9YKm!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!9YKm!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 424w, https://substackcdn.com/image/fetch/$s_!9YKm!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 848w, https://substackcdn.com/image/fetch/$s_!9YKm!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 1272w, https://substackcdn.com/image/fetch/$s_!9YKm!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!9YKm!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png" width="1456" height="751" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:751,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2630103,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/214203824?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!9YKm!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 424w, https://substackcdn.com/image/fetch/$s_!9YKm!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 848w, https://substackcdn.com/image/fetch/$s_!9YKm!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 1272w, https://substackcdn.com/image/fetch/$s_!9YKm!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7cab9f6d-3bfd-4fe9-9860-8c3e795e694a_2680x1382.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong><span>Response rate is not the same as clinical benefit</span></strong></h3><p><span>A high objective response rate can be impressive on a scan, but it does not guarantee longer survival or less toxicity. One recent example is the FDA&#8217;s </span><a href="https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals"><span>withdrawal of adagrasib</span></a><span> for KRAS G12C-mutated metastatic colorectal cancer.</span></p><p><span>The drug had initially received accelerated approval for use in combination with cetuximab through Priority Review and Breakthrough Therapy Designation, based on results from the </span><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2212419"><span>single-arm KRYSTAL-1 trial</span></a><span>. In the subsequent phase 3 study, KRYSTAL-10, the same regimen demonstrated a substantially higher objective response rate than chemotherapy (approximately 47% vs 16%). However, despite this impressive effect, there was no improvement in progression-free survival or overall survival.</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!HpYO!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!HpYO!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 424w, https://substackcdn.com/image/fetch/$s_!HpYO!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 848w, https://substackcdn.com/image/fetch/$s_!HpYO!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!HpYO!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!HpYO!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg" width="1456" height="886" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:886,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:&quot;ESMO GI Figure_Pfieffer&quot;,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="ESMO GI Figure_Pfieffer" title="ESMO GI Figure_Pfieffer" srcset="https://substackcdn.com/image/fetch/$s_!HpYO!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 424w, https://substackcdn.com/image/fetch/$s_!HpYO!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 848w, https://substackcdn.com/image/fetch/$s_!HpYO!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 1272w, https://substackcdn.com/image/fetch/$s_!HpYO!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0d066617-997a-4f42-b0a2-b61140ad50a0_4792x2917.jpeg 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">From <a href="https://dailyreporter.esmo.org/esmo-gastrointestinal-cancers-congress-2026/news/adagrasib-plus-cetuximab-fails-to-outperform-chemotherapy-in-kras-g12c-mutated-metastatic-colorectal-cancer">ESMO Daily Reporter</a> : Figure. Median PFS and median OS in patients with KRAS&#8239;G12C-mutated mCRC randomised to second-line adagrasib plus cetuximab or chemotherapy in the KRYSTAL-10 trial (ESMO Gastrointestinal Cancers Congress 2026, LBA1)</figcaption></figure></div><blockquote><p><strong><span>Based on these results, the FDA withdrew its approval on September 1, 2026, more than two years after the initial approval.</span></strong></p></blockquote><h3><strong><span>Other drugs and indications</span></strong></h3><h4><span>Adagrasib and sotorasib in Non-Small-Cell Lung Cancer</span></h4><p><span>The adagrasib story in colorectal cancer is not unique. When adagrasib was first reviewed for non-small-cell lung cancer, the EMA rejected the application, concluding that the available evidence was insufficient to demonstrate a major therapeutic advantage and that the benefit-risk balance remained uncertain. </span></p><p><span>After re-examination, adagrasib was eventually granted a conditional marketing authorisation. But even then, </span><a href="https://www.ema.europa.eu/en/documents/assessment-report/krazati-epar-public-assessment-report_en.pdf"><span>four CHMP members disagreed</span></a><span> with the approval. In line with the concerns raised during the initial EMA review, they pointed to emerging data from the randomised CodeBreaK 200 trial with sotorasib, another KRAS G12C inhibitor, and questioned whether the level of activity seen with adagrasib was likely to translate into meaningful clinical benefit for patients.</span></p><p><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00221-0/abstract"><span>CodeBreaK 200</span></a><span> had failed to demonstrate an overall survival benefit, though it met its primary endpoint with 1.1-month improvement in progression-free survival (5&#183;6 vs 4&#183;5 months). Nevertheless, several limitations of the trial raised doubts about the robustness of this 1.1-month difference. These included the choice of control arm, substantial dropout in the chemotherapy group, investigator bias and crossover between treatment arms, as well as differences in imaging assessment intervals that may have favoured sotorasib (see </span><a href="https://www.fda.gov/media/172696/download"><span>FDA Briefing Document</span></a><span>, </span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11103877/"><span>Jiang et al.</span></a><span> and </span><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)02035-4/fulltext"><span>Olivier et al.</span></a><span>).</span></p><p><span>Last year, the randomised phase 3 trial of adagrasib versus docetaxel in KRASG12C-mutated non-small cell lung cancer (KRYSTAL-12) also showed no overall survival benefit and only a 1.7-month progression-free survival advantage (7&#183;2 vs 5&#183;5 months). Also, these results remain uncertain because early dropout was considerably higher in the docetaxel arm, which may have affected the progression-free survival analysis.</span></p><p><span>Grade 3 or higher treatment-related adverse events occurred in 47% of patients treated with adagrasib and 46% of patients treated with docetaxel.</span></p><h4><span>Sotorasib in KRAS-Mutated Colorectal Cancer</span></h4><p><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2308795"><span>CodeBreaK 300</span></a><span>, which evaluated sotorasib plus panitumumab versus investigator&#8217;s choice of trifluridine-tipiracil or regorafenib also showed no overall survival benefit and only a 1.7-month progression-free survival advantage (5.6 vs 3.9 months). Nevertheless, also here, </span><a href="https://www.nejm.org/doi/full/10.1056/NEJMc2406109"><span>concerns were raised</span></a><span> about the robustness of the findings due to informative censoring, with substantially more patients censored early in the control arm, potentially affecting the progression-free survival analysis.</span></p><h3><strong><span>Conclusion</span></strong></h3><p><span>The examples above show why we should be </span><strong><span>careful with early signals</span></strong><span>. A waterfall plot can look impressive, and high response rates can create enthusiasm, but they should not be confused with proven clinical benefit.</span></p><p><span>The real test comes in well-designed randomised confirmatory trials against the standard of care. These trials should be adequately powered to assess survival and include standardised patient-reported outcomes to answer the question that really matters: does a treatment that looks promising actually help patients live longer, live better, or both, compared with the existing alternatives?</span></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[Daraxonrasib Is FDA-Approved: Both Good News and Bad News]]></title><description><![CDATA[A key point is in the label: one part is a clear benefit for patients, the other raises far more questions.]]></description><link>https://www.theoncologyshot.com/p/daraxonrasib-is-fda-approved-both</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/daraxonrasib-is-fda-approved-both</guid><pubDate>Thu, 27 Aug 2026 17:49:11 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!3gg8!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Daraxonrasib is an oral RAS(ON) multi-selective, non-covalent inhibitor. In <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2605555">RASolute 302</a>, the product was tested in the second-line setting of patients with metastatic pancreatic cancer, with a median survival gain from 6.7 to 13.2 months. </p><p>The celebration is of course deserved in such a poor-prognosis setting, where so little progress has been made over decades. Yet, these results were reported with a short median follow-up, and the durability of the benefit remains uncertain, with most patients appearing to progress over a year. Together with a challenging toxicity profile, the enthusiasm should also remain measured. (see my previous posts <a href="https://www.theoncologyshot.com/p/rasolute-302-daraxonrasib-in-metastatic">here</a> and <a href="https://www.theoncologyshot.com/p/additional-insights-into-early-daraxonrasib">here</a>)</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!3gg8!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!3gg8!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 424w, https://substackcdn.com/image/fetch/$s_!3gg8!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 848w, https://substackcdn.com/image/fetch/$s_!3gg8!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 1272w, https://substackcdn.com/image/fetch/$s_!3gg8!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!3gg8!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png" width="1456" height="750" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/dc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:750,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2814285,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/213014493?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!3gg8!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 424w, https://substackcdn.com/image/fetch/$s_!3gg8!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 848w, https://substackcdn.com/image/fetch/$s_!3gg8!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 1272w, https://substackcdn.com/image/fetch/$s_!3gg8!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdc21bc8e-3f84-4155-88bf-a00b64f693bb_2684x1382.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h2>Rapid FDA Approval and Rapid Access in The Second-Line Setting - Good News</h2><p>The benefit seen in RASolute 302 is beyond dispute, and patients and families are naturally eagerly awaiting access to the drug. The agency should be commended for making the drug available in such a remarkably short time frame.</p><h2>The Label May Threaten Equipoise in the First-Line Setting - Bad News</h2><p>In an unusual move, the label did not simply reflect the population studied in RASolute 302, but extended the indication to patients <strong>&#8220;not candidates for multiagent systemic therapy&#8221;.</strong></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!fxIt!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!fxIt!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 424w, https://substackcdn.com/image/fetch/$s_!fxIt!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 848w, https://substackcdn.com/image/fetch/$s_!fxIt!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 1272w, https://substackcdn.com/image/fetch/$s_!fxIt!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!fxIt!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png" width="1456" height="595" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:595,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:275558,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/213014493?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!fxIt!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 424w, https://substackcdn.com/image/fetch/$s_!fxIt!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 848w, https://substackcdn.com/image/fetch/$s_!fxIt!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 1272w, https://substackcdn.com/image/fetch/$s_!fxIt!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F33af5de1-54e7-43bf-8305-e3ce8df90d88_1954x798.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">From: https://www.fda.gov/news-events/press-announcements/fda-approves-first-class-targeted-therapy-metastatic-pancreatic-cancer</figcaption></figure></div><p>This is problematic mainly for 2 reasons : </p><h4>1- Efficacy-Effectiveness Gap</h4><p>It is known that benefits seen in highly selected populations may not hold in less selected ones. This is called the <strong>efficacy - effectiveness gap</strong>. A very telling example is in the first-line setting of patients with advanced hepatocellular carcinoma. While the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa0708857">SHARP trial</a> showed a median overall survival of 10.7 months with sorafenib versus 7.9 months with placebo, patients in real-life settings had a median survival of <a href="https://academic.oup.com/oncolo/article/21/9/1113/6401472">4 months</a> (summary figure below). </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!-063!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!-063!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 424w, https://substackcdn.com/image/fetch/$s_!-063!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 848w, https://substackcdn.com/image/fetch/$s_!-063!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 1272w, https://substackcdn.com/image/fetch/$s_!-063!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!-063!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png" width="1456" height="1090" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1090,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:854256,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/213014493?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!-063!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 424w, https://substackcdn.com/image/fetch/$s_!-063!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 848w, https://substackcdn.com/image/fetch/$s_!-063!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 1272w, https://substackcdn.com/image/fetch/$s_!-063!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F64a32741-2108-41bf-a70f-96c267bd4e2d_2492x1866.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><blockquote><p><strong>In other words, we do not know whether the magnitude of benefit demonstrated in RASolute 302 extends to patients who are &#8220;not candidates for multiagent systemic therapy.&#8221; It cannot be excluded that this population may derive little, or even no benefit at all.</strong></p></blockquote><h4>2- Threatening Equipoise in the First-Line Setting</h4><p>We all know that classifying a patient as <strong>&#8220;not a candidate for multi-agent therapy&#8221;</strong> is far from an objective assessment. Now that daraxonrasib is available, it is likely that some patients who might previously have been considered eligible for multi-agent therapy will instead be classified as &#8220;not a candidate&#8221;.</p><p>Let&#8217;s consider the potential consequences when it comes to first-line testing. Logically, the company has moved to an earlier setting with the RASolute 303 trial. Here is the design:</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!jPvr!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!jPvr!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 424w, https://substackcdn.com/image/fetch/$s_!jPvr!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 848w, https://substackcdn.com/image/fetch/$s_!jPvr!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 1272w, https://substackcdn.com/image/fetch/$s_!jPvr!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!jPvr!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png" width="920" height="528" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:528,&quot;width&quot;:920,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:172180,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/196513133?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!jPvr!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 424w, https://substackcdn.com/image/fetch/$s_!jPvr!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 848w, https://substackcdn.com/image/fetch/$s_!jPvr!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 1272w, https://substackcdn.com/image/fetch/$s_!jPvr!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9924f11e-c4e9-44ee-a909-b27e4153fd95_920x528.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>In RASolute 303, the <strong>third chemotherapy-only control arm</strong> (GnP = gemcitabine plus nabpaclitaxel) is a <strong>classic example of a suboptimal control arm</strong>. GnP does not reflect the range of current first-line standard-of-care options: FOLFIRINOX has demonstrated an OS benefit over gemcitabine alone, and NALIRIFOX over GnP. Even though GnP can be a reasonable first-line option, all options should have been part of a <a href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2788290">&#8220;physician&#8217;s choice&#8221;</a>. </p><p>The risk with such a control arm is simple: patients allocated to GnP might leave the trial in excess to seek a better option outside the trial, and patients leaving might not be the same as those staying. </p><blockquote><p><strong>Now introduce a &#8220;not candidates for multiagent systemic therapy&#8221; label, and here is what could happen: even more patients allocated to the GnP arm may leave the assigned treatment to receive daraxonrasib monotherapy off-trial, and it is possible that a significant proportion of those allocated to the second, &#8220;chemotherapy plus daraxonrasib,&#8221; arm might do the same. As a result, the conduct and interpretation of RASolute 303 could become increasingly challenging.</strong></p></blockquote><h3>Concluding words, and financial toxicity</h3><p>Daraxonrasib is a breakthrough pharmacological advance, with undisputable benefit seen in the second-line setting. </p><blockquote><p><strong>What is troubling is seeing such an advance pushed into settings where the benefit to patients remains unproven, while the commercial incentive is clear.</strong> The price - <a href="https://www.reuters.com/legal/litigation/revolution-medicines-gets-fda-nod-targeted-pancreatic-cancer-drug-2026-08-26/?utm_source=chatgpt.com">around $39,800 per month</a> - is particularly telling and risks further fueling the rampant problem of financial toxicity.</p></blockquote><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[Beyond Cross-Trial Comparisons: What Digitized Survival Curves Can Really Tell Us]]></title><description><![CDATA[In today&#8217;s guest post, it&#8217;s my great pleasure to welcome Yago Garitaonaindia and Marco Donia.]]></description><link>https://www.theoncologyshot.com/p/beyond-cross-trial-comparisons-what</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/beyond-cross-trial-comparisons-what</guid><dc:creator><![CDATA[Yago Garitaonaindia]]></dc:creator><pubDate>Wed, 05 Aug 2026 11:00:52 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!2rjN!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>In today&#8217;s guest post, it&#8217;s my great pleasure to welcome Yago Garitaonaindia and Marco Donia. The power of reconstructed datasets from published curves cannot be overstated. In a series of three peer-reviewed 2026 publications, they demonstrate the clinical and research relevance of such methods. If not already, you should follow them closely! (+ on social media <a href="https://www.linkedin.com/in/yagogarita/">Yago</a> and <a href="https://www.linkedin.com/in/marcodonia/">Marco</a>). Enjoy the post! Timoth&#233;e</p><div><hr></div><h3 style="text-align: justify;">Do not make cross-trial comparisons&#8230; Or maybe do?</h3><p style="text-align: justify;">As medical students and repeatedly thereafter, we are taught not to make comparisons across separate clinical trials. </p><blockquote><p style="text-align: justify;">Yet almost every discussion at ASCO or ESMO eventually includes some variation of the same sentence: <strong>&#8220;</strong><em><strong>We should not make cross-trial comparisons, but&#8230;</strong></em>&#8221;<span> </span>and what follows is usually a comparison of two medians, thinking that the elegant disclaimer somehow neutralised its inherent bias.</p></blockquote><p style="text-align: justify;">The reconstruction method, <a href="https://link.springer.com/article/10.1186/1471-2288-12-9">developed by Guyot and colleagues</a>, allows to refine this approach. By extracting the published Kaplan&#8211;Meier coordinates and combining them with the reported numbers at risk, we can reconstruct a plausible set of pseudo individual patient data (pseudo-IPD) that closely reproduces the aggregate survival trajectories in the trial. </p><p style="text-align: justify;"><strong>With such datasets, we can now &#8220;cross-trial&#8221; compare complete survival distributions, restricted mean survival times (RMST), landmark outcomes, or model-derived hazard ratios rather than simply placing two medians side by side.</strong></p><p style="text-align: justify;">Here we discuss some examples of &#8211; in our opinion - useful applications of the Kaplan-Meier reconstruction, including granular cross-trial comparisons generating meaningful evidence.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!2rjN!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!2rjN!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 424w, https://substackcdn.com/image/fetch/$s_!2rjN!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 848w, https://substackcdn.com/image/fetch/$s_!2rjN!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 1272w, https://substackcdn.com/image/fetch/$s_!2rjN!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!2rjN!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png" width="1456" height="750" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:750,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1080907,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/209791160?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!2rjN!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 424w, https://substackcdn.com/image/fetch/$s_!2rjN!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 848w, https://substackcdn.com/image/fetch/$s_!2rjN!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 1272w, https://substackcdn.com/image/fetch/$s_!2rjN!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F42eabee2-02c0-41a8-bcac-94002a6245df_1711x881.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3 style="text-align: justify;">In patients who benefit, what happens next?</h3><p style="text-align: justify;">As immune checkpoint inhibitors (ICI) approvals have expanded, the proportion of patients eligible for these drugs has increased substantially (<a href="http://onlinelibrary.wiley.com/doi/10.1002/ijc.35347">Haslam et al. 2025</a>)<span>. </span>The proportion estimated to respond has also increased, but far less dramatically. Reconstructed datasets, beyond treatment allocation, event or censoring times, don&#8217;t provide information about patients&#8217; other characteristics. As such, reconstruction cannot explain why most treated patients do not respond.</p><blockquote><p style="text-align: justify;"><strong>In contrast</strong>, by allowing one to explore different time-period within a dataset, reconstructed data-sets <strong>can address</strong> a complementary and surprisingly neglected question: <em><strong>What happens later to the patients who benefited initially?</strong></em></p></blockquote><p style="text-align: justify;">In a work recently published in <em><a href="https://jnccn.org/view/journals/jnccn/24/6/article-p244.xml">Journal of the National Comprehensive Cancer Network</a></em> (JNCCN), we wanted to explore what happen to patients with acquired resistance after immune checkpoint blockade. Even though a uniform definition is lacking, acquired resistance is broadly defined as disease progression after an initial clinical benefit. </p><blockquote><p style="text-align: justify;">In our work, we isolated, in reconstructed datasets, the group of patients who have demonstrated an initial benefit over the first 6-months landmark, and examine their subsequent trajectory.</p></blockquote><p style="text-align: justify;">We estimated that <strong>incidence of acquired resistance was 73.5% at three years</strong>. In other words, approximately three quarters were no longer progression-free by that time despite having demonstrated sustained initial benefit. This first descriptive result, given the widespread use of immunotherapy, highlights that <strong>acquired resistance represent a major global clinical burden</strong>.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!jTf6!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!jTf6!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 424w, https://substackcdn.com/image/fetch/$s_!jTf6!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 848w, https://substackcdn.com/image/fetch/$s_!jTf6!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 1272w, https://substackcdn.com/image/fetch/$s_!jTf6!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!jTf6!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png" width="1456" height="1029" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1029,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:649275,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/209791160?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!jTf6!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 424w, https://substackcdn.com/image/fetch/$s_!jTf6!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 848w, https://substackcdn.com/image/fetch/$s_!jTf6!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 1272w, https://substackcdn.com/image/fetch/$s_!jTf6!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa3f8e082-0973-44d3-b45b-205cfe632c99_1924x1360.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Adapted from <a href="https://jnccn.org/view/journals/jnccn/24/6/article-p244.xml">Garitaonaindia et al. JNCCN 2026</a> </figcaption></figure></div><blockquote><p style="text-align: justify;">We wanted to go deeper: <strong>our analysis also suggested that the risk of acquired resistance was surprisingly not dependent on tumour histology, but rather on response depth.</strong></p></blockquote><p style="text-align: justify;">We sought to confirm this in a large nationwide study involving patients with melanoma, NSCLC and renal cell carcinoma who had achieved an objective response. In this work, published in 2026 in the <em>European Journal of Cancer</em> (openly available <a href="https://www.ejcancer.com/article/S0959-8049(26)00653-2/fulltext">here</a>), we found that outcomes were strikingly similar across tumour types once patients were grouped according to response category: partial response or complete response.</p><p style="text-align: justify;"><strong>First conclusion:</strong> reconstructing curves allowed us to estimate the burden of acquired resistance, which is massive. Then it suggested that the risk of acquired resistance is likely to be tumor-agnostic, and strongly associated with the depth of response, a finding we could replicate in the real-world.</p><h3 style="text-align: justify;">Exploring biological subgroups across trials</h3><p style="text-align: justify;"><strong>A second potential role of reconstructed data is pooled subgroup analysis.</strong> When curves are reported by PD-L1 expression, mutation status, disease stage or radiological response, reconstructed datasets then allow to pool these estimates across trials. </p><p style="text-align: justify;">Pathological complete response (pCR) offers a particularly informative example. Patients achieving pCR have received (neo-adjuvant) treatment, undergone surgery and been found to have no viable residual tumour on pathological examination. Again, this does not remove differences in stage, regimen, surgery, tumour biology or subsequent therapy. Moreover, because pCR is a post-treatment variable influenced by both treatment and underlying prognosis, conditioning on it introduces its own selection considerations. </p><blockquote><p style="text-align: justify;"><strong>Nevertheless, pCR defines a clinically homogeneous post-treatment state, compared to other analyses based exclusively on a single mutation or baseline biomarker.</strong></p></blockquote><p style="text-align: justify;">In a work just published in <em>the <a href="https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djag197/8711507">Journal of the National Cancer Institute</a></em>, we reconstructed survival outcomes among patients achieving pCR after neoadjuvant or perioperative immunotherapy-based treatment.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!iZEJ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!iZEJ!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 424w, https://substackcdn.com/image/fetch/$s_!iZEJ!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 848w, https://substackcdn.com/image/fetch/$s_!iZEJ!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 1272w, https://substackcdn.com/image/fetch/$s_!iZEJ!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!iZEJ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png" width="1456" height="1284" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1284,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:293565,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/209791160?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!iZEJ!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 424w, https://substackcdn.com/image/fetch/$s_!iZEJ!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 848w, https://substackcdn.com/image/fetch/$s_!iZEJ!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 1272w, https://substackcdn.com/image/fetch/$s_!iZEJ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F493d6e22-70b0-4c88-8a25-c2d751b2f051_1528x1348.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Adapted from <a href="https://academic.oup.com/jnci/advance-article/doi/10.1093/jnci/djag197/8711507">Garitaonaindia et al. JNCI 2026</a></figcaption></figure></div><blockquote><p style="text-align: justify;"><strong>Where comparisons between neoadjuvant-only and perioperative were feasible, postoperative immunotherapy was not associated with a clear improvement in event-free survival among patients who had already achieved pCR.</strong> This analysis provides a signal that the routine administration of additional therapy in all patients with pCR deserves prospective testing rather than automatic acceptance.</p></blockquote><h3 style="text-align: justify;">From trial &#8220;efficacy&#8221; to delivered &#8220;effectiveness&#8221;: benchmarking the gap</h3><p style="text-align: justify;">A third utilisation of reconstructed data is to describe and quantify what is called the efficacy-effectiveness gap.</p><p style="text-align: justify;">Pivotal oncology trials frequently exclude substantial proportions of the patients who will ultimately receive the treatment after approval. However, real-world studies have shown that in less selected populations, the observed outcomes (which is now called &#8220;effectiveness&#8221;) are less pronounced, or can even no longer be present.</p><blockquote><p style="text-align: justify;">Comparing reconstructed data with real-world data &#8220;without any matching&#8221; provides an highly clinically relevant information : &#8220;<em><strong>How far do the outcomes delivered in routine practice deviate from the outcomes that justified approval and reimbursement?&#8221;</strong></em></p></blockquote><p style="text-align: justify;">We addressed this question in metastatic melanoma by comparing reconstructed data from pivotal trials with individual-level data from a nationwide clinical registry. Our work has just been published, and is available <a href="https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djag196/8709960">here</a>. We examined the real-world population both as a whole, and after applying the main pivotal-trial eligibility criteria. <strong>The results showed that the efficacy&#8211;effectiveness gap was not uniform across treatments.</strong> </p><p style="text-align: justify;">1 &#8594; For anti-PD-1 monotherapy, real-world patients who met the major trial eligibility criteria had outcomes broadly aligned with the pivotal-trial benchmark. The deviation was concentrated predominantly among trial-ineligible patients.</p><p style="text-align: justify;">2 &#8594; For BRAF/MEK inhibition, however, the gap was larger and remained evident even among patients who were formally trial-eligible. Eligibility alone could not explain the divergence. In this case, we believe a likely contributor was confounding by indication, because the population selected to receive this combination therapy in routine practice was possibly shaped by various factors, including the availability and positioning of competing treatments. Even though these patients might formally meet the eligibility criteria of the pivotal trial, they still differ materially from the trial population.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!DRyf!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!DRyf!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 424w, https://substackcdn.com/image/fetch/$s_!DRyf!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 848w, https://substackcdn.com/image/fetch/$s_!DRyf!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 1272w, https://substackcdn.com/image/fetch/$s_!DRyf!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!DRyf!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png" width="1456" height="1144" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1144,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:311340,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/209791160?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!DRyf!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 424w, https://substackcdn.com/image/fetch/$s_!DRyf!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 848w, https://substackcdn.com/image/fetch/$s_!DRyf!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 1272w, https://substackcdn.com/image/fetch/$s_!DRyf!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8b0645fc-18ce-449a-9da9-8148f9c3ed7d_1542x1212.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Adapted from <a href="https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djag196/8709960">Garitaonaindia et al. JNCI 2026</a></figcaption></figure></div><h3 style="text-align: justify;">Reconstruction should not be a substitute for data sharing</h3><p style="text-align: justify;">These <strong>three examples</strong> illustrate various uses of reconstruction that extend beyond conventional cross-trial treatment comparisons:</p><ol><li><p style="text-align: justify;">A temporal landmark can recover the subsequent trajectory of patients who have already benefited from therapy. </p></li><li><p style="text-align: justify;">A post-treatment state such as pCR can define a clinically coherent population in which residual risk and the potential contribution of further treatment can be explored. </p></li><li><p style="text-align: justify;">Reconstructed data allowed to granularly describe the efficacy-effectiveness gap, which may have broad application for patients and societies.</p></li></ol><blockquote><p style="text-align: justify;"><strong>What can already be achieved by extracting data from published curves illustrates how much more could be accomplished with access to the underlying patient-level data.</strong> </p></blockquote><p style="text-align: justify;">Responsible data sharing would allow to ask more refined questions, obtain more precise answers, and identify unmet needs and emerging problems earlier. This would also benefit industry as a whole, by improving evidence generation and informing future drug development, but its greatest value would be for patients, both those treated today and those who participated in the original trials.</p><p style="text-align: justify;">Patients entered those trials with the understanding that their contribution would help advance science. Honouring that commitment requires that the data generated become more timely and broadly accessible for responsible independent research under appropriate governance.</p><p style="text-align: justify;">Kaplan&#8211;Meier curves are not merely images; they are data that we have learned to unlock. We believe these should not be the only trial data independent researchers should be able to access when primary results of major clinical trials are published.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p style="text-align: justify;"></p>]]></content:encoded></item><item><title><![CDATA[Sham Controls and Tumor Treating Fields: Does the Ethical Argument Hold?]]></title><description><![CDATA[Our new paper published in the European Journal of Cancer highlight current limitations regarding the efficacy of TTFs in oncology.]]></description><link>https://www.theoncologyshot.com/p/sham-controls-and-tumor-treating</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/sham-controls-and-tumor-treating</guid><dc:creator><![CDATA[Sahar van Waalwijk]]></dc:creator><pubDate>Sat, 11 Jul 2026 10:38:38 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!dRga!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Today, we are covering our new work just published in <em>The European Journal of Cancer</em>, entitled <strong><a href="https://www.ejcancer.com/article/S0959-8049(26)00678-7/fulltext">&#8220;Tumor treating fields: Will the evidence gap ever be filled?&#8221;</a></strong>. We thank our co-authors Sruthi Ranganathan, <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Susannah Ellsworth&quot;,&quot;id&quot;:6793799,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:null,&quot;uuid&quot;:&quot;f29fa40a-b20f-4a8a-aaf4-a9f5a624a335&quot;}" data-component-name="MentionToDOM"></span>, and Alessandro Hammond! </p><div><hr></div><h3>What is a sham-control?</h3><p><span>When you take a pill, part of the benefit may come from placebo effects. The same can be true for medical devices. For example, with a wearable that you have to put on for 18 hours a day, expectations, routine, support and coaching may drive the effect. To show that a device really works, it is important to blind patients and investigators in a sham-controlled randomised trial. (more on this </span><a href="https://pubmed.ncbi.nlm.nih.gov/30076810/"><span>here</span></a><span>, and </span><a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC10288945/"><span>here</span></a><span>).</span></p><p><span>Sham controls are like placebo controls, but instead of a placebo drug, patients receive a version of the device or procedure without the active therapeutic component. </span></p><blockquote><p><strong><span>Placebo effects from devices can be </span><a href="https://pubmed.ncbi.nlm.nih.gov/16452103/"><span>even greater than those from pills</span></a><span>. And a device can come with extra-care potentially influencing patients&#8217; outcomes.</span></strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!dRga!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!dRga!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 424w, https://substackcdn.com/image/fetch/$s_!dRga!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 848w, https://substackcdn.com/image/fetch/$s_!dRga!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 1272w, https://substackcdn.com/image/fetch/$s_!dRga!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!dRga!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png" width="1456" height="859" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:859,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2616248,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/203926734?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!dRga!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 424w, https://substackcdn.com/image/fetch/$s_!dRga!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 848w, https://substackcdn.com/image/fetch/$s_!dRga!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 1272w, https://substackcdn.com/image/fetch/$s_!dRga!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F0e0707b2-ab7f-4f9a-88b0-b5ba68a3813f_2350x1386.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3>Does the Ethical Argument Hold?</h3><p>Tumor treating fields (TTFs) deliver low-intensity electric fields through a <strong>device connected to adhesive pads</strong> placed on the patient&#8217;s skin, aiming to exert direct antitumor activity mainly through mitotic disruption, with additional hypothesized effects on DNA damage, oxidative stress, immune activation, autophagy, and blood&#8211;brain barrier permeability. However, the <strong>biologic plausibility remains insufficiently validated</strong>. Rigorous human in vivo dosimetry is lacking, clinicopathologic validation is limited, and effects on normal proliferative tissues are not clearly observed. </p><p>Nonetheless, <strong>some TTFs trials have reported a survival benefit</strong>, these are the <a href="https://jamanetwork.com/journals/jama/fullarticle/2666504">EF-14</a> trial in glioblastoma, the <a href="https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00344-3/fulltext">LUNAR trial</a> in lung cancer, and the <a href="https://ascopubs.org/doi/10.1200/JCO-25-00746">PANOVA-3 trial</a> in pancreatic cancer. </p><p>We posit that without a sham-control trial, the exact contribution of the electric fields cannot be isolated : </p><blockquote><p><strong>&#8220;In oncology, where progression-free survival (PFS) and overall survival (OS) are not subjective outcomes, sham control could be seen as unnecessary, or even unethical. This would overlook a key component of TTF use: the co-interventions and the intensity of care associated with the device. With TTFs, patients and their families not only receive the device, but also additional support and infrastructure around its use, such as 24/7 assistance, home deliveries, and increased home-based interactions for device management, including regular array changes.&#8221;</strong></p></blockquote><p>For instance, there are a numbers of trials showing that early palliative care improved survival in patients with advanced cancer. Moreover, the magnitude of benefit reported in those trials is comparable with that reported in TTFs trials reporting a survival gain, like in glioblastoma in the EF-14 trial. (see figure below). </p><div class="captioned-image-container"><figure><div class="image-link image2" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!rK9D!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 424w, https://substackcdn.com/image/fetch/$s_!rK9D!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 848w, https://substackcdn.com/image/fetch/$s_!rK9D!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 1272w, https://substackcdn.com/image/fetch/$s_!rK9D!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!rK9D!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png" width="1456" height="295" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:295,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:97892,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/203926734?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!rK9D!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 424w, https://substackcdn.com/image/fetch/$s_!rK9D!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 848w, https://substackcdn.com/image/fetch/$s_!rK9D!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 1272w, https://substackcdn.com/image/fetch/$s_!rK9D!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29b249aa-c015-40a4-b634-be5f64188f84_1498x303.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div></div></div></div><figcaption class="image-caption">Key overall survival trial data from a systematic review on early palliative care, with the EF-14 trial data added on the figure (original publication <a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011129.pub2/full">here</a>).</figcaption></figure></div><p>In other words, it is not excluded that the survival benefit seen with TTFs may have been driven by the extra-care associated with the device, rather than by the electric fields themselves. </p><blockquote><p>&#8220;<strong>In order to isolate the specific effect of TTFs</strong> from that of the care accompanying the device use, the most rigorous approach would be a sham-controlled trial using a device identical in appearance but not delivering electric fields. <strong>Yet, throughout TTF development, no trials have used a sham control.</strong> One might argue that they would pose an <strong>ethical dilemma: how could we expose patients to the physical burden of TTFs, without any active intervention, without the electric fields?</strong> However, this <strong>ethical critique fails in two ways</strong>. First, if that burden cannot be ethically justified for control-arm patients, then we should also question whether it is appropriate to impose the same burden on patients in the experimental arm. <strong>Second, without a sham-controlled trial, it is possible we are exposing thousands of patients to a therapy that may have no benefit in and of itself - an uncertainty that raises even greater ethical concerns.</strong>&#8221;</p></blockquote><h3>Suboptimal control arms and changes in sample sizes</h3><p><span>We identified six completed randomized trials studying TTFs. A first concern is that 3 out of 6 used suboptimal control arm. (see Table 1). Detailed</span> explanations on each of these trial and their control group are available in our manuscript.</p><blockquote><p><strong>&#8220;A survival gain observed against a weaker comparator may not persist when compared with the best available care.&#8221;</strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!zCfj!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!zCfj!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 424w, https://substackcdn.com/image/fetch/$s_!zCfj!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 848w, https://substackcdn.com/image/fetch/$s_!zCfj!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 1272w, https://substackcdn.com/image/fetch/$s_!zCfj!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!zCfj!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png" width="1456" height="799" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/c82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:799,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:552680,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/203926734?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!zCfj!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 424w, https://substackcdn.com/image/fetch/$s_!zCfj!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 848w, https://substackcdn.com/image/fetch/$s_!zCfj!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 1272w, https://substackcdn.com/image/fetch/$s_!zCfj!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc82f76e5-96e3-48fc-9e8e-50f345f42d2f_2222x1220.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Another concern relates to <strong>sample size modifications</strong>. In one trial, LUNAR, the sample size was lower than initially planned, raising the risk of a spurious finding. In another trial, PANOVA-3, the final sample size was greater than originally planned, with final results at the cusp of significance. Was this increase planned? What was the explanation? Would the results have remained significant had the sample size been as originally planned?</p><h3><span>Without regulatory requirements, evidence may never be delivered</span></h3><blockquote><p>First, we noted : &#8220;TTFs occupy a uniquely isolated evidentiary position: the entire pivotal evidence, implementation infrastructure, and post-market data are concentrated within a single sponsor. <strong>This concentration is not inherently disqualifying, but it amplifies the importance of even more careful scrutiny.</strong>&#8221;</p></blockquote><p><span>In both the United States and Europe, regulators allow greater flexibility for medical devices than for drugs. In the US, approval is based on &#8220;reasonable assurance of safety and effectiveness&#8221; and &#8220;least burdensome&#8221; principles, while in Europe devices can obtain CE marking without requiring sham-controlled trials. Regulators rely in part on post-market clinical follow-up (PMCF) to address remaining uncertainties, but in practice these data are often not publicly available or incomplete. As a result, devices can enter clinical practice with substantial uncertainty regarding their clinical benefit, and the evidence gap may not ever be closed.</span></p><p>Check out our full manuscript <a href="https://www.sciencedirect.com/science/article/pii/S0959804926006787">here</a> for deeper insights, as well as a prior publication on the LUNAR trial that was published with <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Vinay Prasad&quot;,&quot;id&quot;:21798998,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:&quot;https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8d9b3de5-2e57-4d32-a0d4-99f8431caa20_8688x5792.jpeg&quot;,&quot;uuid&quot;:&quot;b4027e9f-c768-4087-a5d2-232a57b31ebb&quot;}" data-component-name="MentionToDOM"></span> (<a href="https://www.sciencedirect.com/science/article/pii/S1936523325001287?via%3Dihub">here</a>).</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[EMA and FDA Advocate Removing Amgen’s Drug from the Market: How Unblinded Personnel Manipulated the ADVOCATE Trial]]></title><description><![CDATA[It&#8217;s my pleasure to welcome back Sahar Van Waalwijk, who covers an important topic following an unusual development.]]></description><link>https://www.theoncologyshot.com/p/ema-and-fda-advocate-removing-amgens</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/ema-and-fda-advocate-removing-amgens</guid><dc:creator><![CDATA[Sahar van Waalwijk]]></dc:creator><pubDate>Thu, 09 Jul 2026 20:01:47 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!HUIY!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>It&#8217;s my pleasure to welcome back <a href="https://scholar.google.com/citations?user=i8XnnMEAAAAJ&amp;hl=en">Sahar Van Waalwijk</a>, who covers an important topic following an unusual development. Enjoy! Timoth&#233;e</p><div><hr></div><p><span>Imagine a wine competition. Judges taste wines from unlabelled bottles and score them without knowing which winery produced them. This prevents famous brands from receiving more favourable scores simply because of their reputation. Now imagine that all the wines have been scored and the bottles have been &#8220;unblinded&#8221;, allowing the judges to see which winery produced each wine. But then, without telling anyone, they go back and revise some of the scores. This would be regarded as foul play, as it undermines the integrity of the competition and may disadvantage wineries whose products were originally rated more highly.</span></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!HUIY!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!HUIY!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 424w, https://substackcdn.com/image/fetch/$s_!HUIY!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 848w, https://substackcdn.com/image/fetch/$s_!HUIY!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 1272w, https://substackcdn.com/image/fetch/$s_!HUIY!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!HUIY!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png" width="1456" height="770" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:770,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:4918029,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/206341632?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!HUIY!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 424w, https://substackcdn.com/image/fetch/$s_!HUIY!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 848w, https://substackcdn.com/image/fetch/$s_!HUIY!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 1272w, https://substackcdn.com/image/fetch/$s_!HUIY!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4fcc2689-1f93-41f2-9126-9665308ed14e_2612x1382.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><span>Manipulating study results</span></h3><p><span>Now imagine if the same thing happened in a blinded clinical trial. A change in outcome assessment can alter the conclusions of a study and potentially affect which medicines are approved, funded, and prescribed to patients. In the worst case, patients may receive treatments that cause more harm than benefit.</span></p><p><span>Remarkably, this is exactly what the </span><a href="https://www.fda.gov/drugs/drug-alerts-and-statements/cder-proposes-withdraw-approval-tavneos"><span>FDA</span></a><span> alleges happened in the </span><a href="https://www.nejm.org/doi/10.1056/NEJMe2608684"><span>ADVOCATE trial</span></a><span> of avacopan (Tavneos), a drug of Amgen. According to the FDA, information that came to light more than three years after approval showed that </span><strong><span>&#8220;unblinded study personnel manipulated the results of the pivotal clinical study so the drug looked effective when the original analysis did not support that conclusion. The applicant also did not disclose the original analysis to FDA, in violation of FDA regulations.&#8221;</span></strong></p><p><span>The same conclusion was recently reached by the </span><a href="https://www.ema.europa.eu/en/news/ema-recommends-revoking-marketing-authorisation-tavneos"><span>EMA</span></a><span>, which had issued a positive opinion on the drug just one month after the FDA&#8217;s approval in 2021. </span></p><blockquote><p><span>The EMA now concludes that </span><strong><span>&#8220;Advocate study was conducted in breach of good clinical practice (GCP)&#8221; and the data submitted for the registration &#8220;were found to be incorrect and misleading&#8221;.</span></strong></p></blockquote><h3><span>Serious harm</span></h3><p><span>Avacopan is authorised for treating adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), two rare inflammatory conditions of the blood vessels.</span></p><p><span>EMA writes however that this drug &#8220;is associated with an increased risk of drug-induced liver injury (DILI) and vanishing bile duct syndrome (VBDS, a rare condition where the small bile ducts inside the liver are gradually damaged and disappear over time), including cases with a fatal outcome&#8230;&#8221; Also </span><a href="https://www.fda.gov/media/191708/download?attachment"><span>FDA</span></a><span> is increasingly concerned about the safety profile of avacopan.</span></p><h3><span>Advocating for the retraction of ADVOCATE</span></h3><p><span>Last week, the New England Journal of Medicine (NEJM) retracted the landmark ADVOCATE trial publication after two academic authors requested its withdrawal. According to the </span><strong><a href="https://www.nejm.org/doi/10.1056/NEJMe2608684"><span>retraction notice</span></a></strong><span>, they were unaware that primary endpoint assessments for nine patients had been re-adjudicated after database lock and trial unblinding.</span></p><p><span>In the ADVOCATE study, patients with GPA or MPA were randomised to receive either avacopan or placebo, both in addition to standard treatment (either rituximab or cyclophosphamide followed by azathioprine). The placebo group also received a 20-week course of high-dose corticosteroids. According to the now-retracted ADVOCATE publication, avacopan was reported to be at least as effective as corticosteroids in inducing remission and to provide higher sustained remission rates at 52 weeks.</span></p><h3><span>What happens next?</span></h3><p><span>In the EU, EMA has recommended that the medicine&#8217;s marketing authorisation be revoked. If this recommendation is confirmed by the European Commission, avacopan will no longer be authorised in the EU. In the US, the drug will remain on the market until either the applicant decides to withdraw it or the FDA Commissioner orders its removal. If the applicant requests a hearing, the FDA Commissioner will first decide whether to hold one and will subsequently decide whether approval of avacopan should be withdrawn.</span></p><h3><span>Trust is hard to earn, easy to lose</span></h3><p><span>In a foul wine competition, consumers are not harmed much. In the worst case, they end up with a wine they do not like and do not get value for their money. The avacopan case is a different story. Here, many patients were exposed to serious side effects, and healthcare budgets are wasted. Yet both cases have something in common: a loss of trust.</span></p><blockquote><p><strong><span>Manipulating data affects trust in science itself. It is uncomfortable to think that cases like this may only occasionally come to light, raising the question of how many similar cases go unnoticed.</span></strong></p></blockquote><p><span>It also raises questions about the role of academic investigators participating in industry-sponsored trials. If a sponsor does not consider it important to disclose deviations or breaches of this nature, what is the purpose of co-authoring their publications?</span></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p>]]></content:encoded></item><item><title><![CDATA[Additional Insights Into Early Daraxonrasib Data]]></title><description><![CDATA[Let&#8217;s take a deep dive into the early-phase data on daraxonrasib in patients with metastatic pancreatic cancer, just published in the New England Journal of Medicine.]]></description><link>https://www.theoncologyshot.com/p/additional-insights-into-early-daraxonrasib</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/additional-insights-into-early-daraxonrasib</guid><pubDate>Tue, 19 May 2026 20:04:11 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!1kY8!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Daraxonrasib is making headlines. A few weeks ago, a <a href="https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/">press release</a> reported positive phase 3 results from the RASolute 302 trial in second-line metastatic pancreatic cancer, with particular emphasis on a secondary endpoint: overall survival in all patients. Full data are <a href="https://www.asco.org/abstracts-presentations/268016">expected</a> at the upcoming American Society of Clinical Oncology annual meeting. See my previous post for what to watch for when the full data are presented (<a href="https://www.theoncologyshot.com/p/rasolute-302-daraxonrasib-in-metastatic">here</a>).</p><p>Now, the phase 1b/2 data have finally been published in <em><a href="https://www.nejm.org/doi/10.1056/NEJMoa2505783">The New England Journal of Medicine</a></em>. </p><p><strong>A quick recap: daraxonrasib inhibits the active RAS(ON) form. Because even RAS wild-type tumors may depend on RAS activation, this provides the rationale for investigating daraxonrasib beyond RAS-mutant populations.</strong> </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!1kY8!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!1kY8!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 424w, https://substackcdn.com/image/fetch/$s_!1kY8!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 848w, https://substackcdn.com/image/fetch/$s_!1kY8!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 1272w, https://substackcdn.com/image/fetch/$s_!1kY8!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!1kY8!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png" width="1456" height="811" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:811,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:3887012,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/198408443?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!1kY8!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 424w, https://substackcdn.com/image/fetch/$s_!1kY8!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 848w, https://substackcdn.com/image/fetch/$s_!1kY8!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 1272w, https://substackcdn.com/image/fetch/$s_!1kY8!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F2e2b727e-8141-4fe0-be7d-1156adf404d3_2748x1530.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3><strong>Response rates: which number matters?</strong></h3><p>In most early phase data, response rates are not the primary endpoint, which is often safety measures. In RMC-6236-001, this was the case, yet <strong>the abstract emphasizes the most favorable response-rate metrics.</strong></p><blockquote><p>&#8220;In a subgroup of 26 patients with <em>RAS</em> G12 mutations who were treated with <strong>second-line daraxonrasib</strong> at a dose of 300 mg, an objective response to therapy was reported in <strong>35%</strong> (95% confidence interval [CI], 17 to 56).[&#8230;] Among the 38 patients with <em>RAS</em> G12, G13, or Q61 mutations, <strong>29%</strong> (95% CI, 15 to 46) had an objective response.&#8221;</p></blockquote><p>However, there are many response rates in RMC-6236-001</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!s6TZ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!s6TZ!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 424w, https://substackcdn.com/image/fetch/$s_!s6TZ!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 848w, https://substackcdn.com/image/fetch/$s_!s6TZ!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 1272w, https://substackcdn.com/image/fetch/$s_!s6TZ!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!s6TZ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png" width="1456" height="474" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:474,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:385093,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/198408443?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!s6TZ!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 424w, https://substackcdn.com/image/fetch/$s_!s6TZ!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 848w, https://substackcdn.com/image/fetch/$s_!s6TZ!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 1272w, https://substackcdn.com/image/fetch/$s_!s6TZ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F85a1100f-37d5-4464-9bca-c20ed38aa192_2390x778.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">In red, ORR values reported in the abstract. In green, key other relevant ORR values. (data derived from Table 3, RMC-6236-001)</figcaption></figure></div><p>In small phase 1/2 trials, with highly selected patients, the relevance of breaking down the results according to the line of therapy is not as obvious as in larger phase 3 trials. </p><blockquote><p><strong>The response rate in the overall treated population (24%), together with the breakdown by RAS status (with 27% in G12-mutant population), are both highly relevant, yet not explicitly reported as standalone values by the authors. </strong></p></blockquote><h3><strong>Comparison with other studies</strong></h3><p>Here is an informal contextualization with prior selected trials in a comparable setting (<strong>disclaimer, this is not a systematic review!</strong>). </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!dxgz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!dxgz!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 424w, https://substackcdn.com/image/fetch/$s_!dxgz!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 848w, https://substackcdn.com/image/fetch/$s_!dxgz!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 1272w, https://substackcdn.com/image/fetch/$s_!dxgz!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!dxgz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png" width="1456" height="770" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:770,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:226630,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/198408443?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!dxgz!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 424w, https://substackcdn.com/image/fetch/$s_!dxgz!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 848w, https://substackcdn.com/image/fetch/$s_!dxgz!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 1272w, https://substackcdn.com/image/fetch/$s_!dxgz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F51609c04-c07a-4c43-ace0-408406267d61_2348x1242.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong>In this figure, ORRs are reported for the overall study population of each trial, with no breakdown according to line of therapy.</strong> </p><p>Importantly, the characteristics of the populations included varied across studies. In <strong><a href="https://www.sciencedirect.com/science/article/pii/S0140673615009861">NAPOLI-1</a></strong>, 53% of patients received NALIRI as second-line therapy in the metastatic setting, 34% as later-line treatment, and 13% had previously received systemic therapy, although not in the metastatic setting. In the Japanese study (<strong><a href="https://www.ejcancer.com/article/S0959-8049(25)00205-9/abstract">jRCTs031210040</a></strong>), all patients had metastatic pancreatic cancer refractory to first-line gemcitabine-based chemotherapy, with no further detailed breakdown reported. In <strong><a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2208470">CodeBreaK 100</a></strong>, 55% of patients had stage IV disease at initial diagnosis, and all patients had metastatic disease at enrollment; 79% had received two or more prior lines of therapy. In <strong><a href="https://ascopubs.org/doi/10.1200/JCO.23.00434">KRYSTAL-1</a></strong>, 76% of patients had received two or more lines of systemic therapy before enrollment. </p><blockquote><p><strong>Bottom line: early signals of activity, but still within the historical ballpark</strong></p></blockquote><p><strong>The much awaited phase 3 RASolute 302 trial will provide more precise estimates of response rates in a larger and more homogeneous population (second-line therapy in the metastatic setting).</strong></p><h3><strong>Survival?</strong></h3><p>Interpreting survival data from single-arm early-phase trials should be done very cautiously. In order to receive multiple lines of therapy, patients need to be fit enough and likely have a more indolent tumour biology, unlike rapidly progressing cancers that can sometimes lead to death before any therapy can even be administered.</p><p><strong>As a result, and this is somehow counterintuitive, we may see longer survival in later-line early-phase trials than in first-line phase 3 trials.</strong></p><p>An example is durvalumab in urothelial carcinoma. In an <a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2648865">early phase I/II study</a> conducted mostly in previously treated/post-platinum patients, median OS was reported at 18.2 months. However, in the first-line <a href="https://www.sciencedirect.com/science/article/pii/S1470204520305416">phase III DANUBE trial</a>, durvalumab monotherapy showed a shorter median OS: 14.4 months in the PD-L1&#8211;high population and 13.2 months in the ITT population. </p><blockquote><p><strong>As such, caution is warranted when drawing conclusions from PFS or OS data from early-phase trials.</strong></p></blockquote><h3><strong>Toxicity in the 300 mg cohort: more details are needed.</strong></h3><p>Below is a focus on the 300 mg cohort, the dose chosen for phase 3 trials. </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!_fPz!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!_fPz!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 424w, https://substackcdn.com/image/fetch/$s_!_fPz!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 848w, https://substackcdn.com/image/fetch/$s_!_fPz!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 1272w, https://substackcdn.com/image/fetch/$s_!_fPz!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!_fPz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png" width="839" height="1035" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/dfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1035,&quot;width&quot;:839,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:297229,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/198408443?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!_fPz!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 424w, https://substackcdn.com/image/fetch/$s_!_fPz!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 848w, https://substackcdn.com/image/fetch/$s_!_fPz!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 1272w, https://substackcdn.com/image/fetch/$s_!_fPz!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fdfdba8ab-2002-4f85-9f06-5a4c9565be36_839x1035.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Adapted from Table 2, <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2505783">Wolpin et al. N Engl J Med. May 7;394(18):1790-1802.2026.</a></figcaption></figure></div><p>There is a striking difference between the rate of grade &#8805;3 treatment-related adverse events (TRAEs, 34%) and the summed frequency of individual grade &#8805;3 TRAEs occurring in &gt;10% of patients (13%). </p><p>Even though Table S2 reports additional safety data, it still leaves 10 patients with undocumented grade &#8805;3 TRAEs in the 300 mg cohort, since only events leading to dose modification and occurring in &#8805;2% of patients were described.</p><blockquote><p><strong>Toxicity was not dominated by a single adverse event, but rather distributed across multiple less frequent toxicities. However, the type of the remaining unreported grade &#8805;3 TRAEs (12% of patients) is not described.</strong></p></blockquote><h3>Enthusiasm should not hamper cautious appraisal</h3><p>Daraxonrasib shows unquestionable early activity in metastatic RAS-mutated pancreatic cancer. However, the data remain within a range comparable to that observed in other studies. Toxicity is a significant concern, and grade &#8805;3 toxicities are not fully detailed.</p><p>While we can understand the natural enthusiasm in such a poor-prognosis setting, we should at the same time try not to deviate from an objective and thorough appraisal of the data. Looking forward to the upcoming ASCO presentation! (See my <a href="https://www.theoncologyshot.com/p/rasolute-302-daraxonrasib-in-metastatic">previous post</a> on what to look for in the full data presentation.)</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[World-first tumour-agnostic reimbursement for dual immunotherapy (ipilimumab plus nivolumab), an academic debate, and the DART trial]]></title><description><![CDATA[In two back-to-back essays, we and our counterparts reach opposing conclusions regarding the DART trial and broad reimbursement of dual immunotherapy.]]></description><link>https://www.theoncologyshot.com/p/world-first-tumour-agnostic-reimbursement</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/world-first-tumour-agnostic-reimbursement</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Sat, 16 May 2026 11:11:48 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!3IBd!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Imagine you have pain. You would probably start with a single painkiller rather than immediately buying and taking a combination of different painkillers. Combining drugs may increase side effects. Besides, why spend more money if one medicine alone might work just as well? The same principle applies in healthcare systems. For the authorization and reimbursement of combination therapies, it is important to show that the combination truly works better than each drug alone. Besides, regulators, payers, and most clinicians will want clinical evidence and, ideally, predictive markers to figure out who&#8217;s most likely to benefit. This has been the subject of a vigorous debate between <a href="https://www.ejcancer.com/article/S0959-8049(26)00566-6/fulltext">us</a> and our <a href="https://www.ejcancer.com/article/S0959-8049(26)00565-4/abstract">counterparts</a> in the latest issue of the <em>European Journal of Cancer</em>.</p><p>To set the stage, in 2025, an unprecedented decision was made by the Australian Pharmaceutical Benefits Advisory Committee (PBAC) to recommend tumour-agnostic reimbursement of nivolumab with or without ipilimumab for all immunotherapy-sensitive advanced or metastatic cancers (<a href="https://www.pbs.gov.au/industry/listing/elements/pbac-meetings/psd/2025-07/files/nivolumab-plus-ipilimumab-psd-july-2025.pdf">see here</a>). The recommendation allows treatment decisions to rely on clinicians&#8217; <strong>&#8220;appropriate discretion&#8221;</strong> and <strong>&#8220;the best available evidence&#8221;</strong> without providing a clearer definition.</p><blockquote><p><strong>This recommendation could allow for a broad utilization of dual checkpoint inhibition (nivolumab plus ipilimumab) without any biomarker requirement.</strong></p></blockquote><p>Together with our colleague <a href="https://www.esmo.org/about-esmo/biographies/david-thomas">David Thomas</a>, we explain why such a decision sets a concerning precedent. In the same issue of the journal, <a href="https://www.esmo.org/about-esmo/biographies/vivek-subbiah">Vivek Subbiah</a> and <a href="https://www.mcw.edu/find-a-doctor/kurzrock-razelle">Razelle Kurzrock</a> published a counterpoint article as part of a vigorous yet respectful academic debate.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!3IBd!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!3IBd!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 424w, https://substackcdn.com/image/fetch/$s_!3IBd!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 848w, https://substackcdn.com/image/fetch/$s_!3IBd!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 1272w, https://substackcdn.com/image/fetch/$s_!3IBd!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!3IBd!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png" width="1456" height="808" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/c8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:808,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:3678395,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/197656084?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!3IBd!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 424w, https://substackcdn.com/image/fetch/$s_!3IBd!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 848w, https://substackcdn.com/image/fetch/$s_!3IBd!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 1272w, https://substackcdn.com/image/fetch/$s_!3IBd!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fc8a5be62-b8dc-4f58-930b-e2b30019c308_2804x1556.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3>A survival benefit of dual immunotherapy alone over anti-PD(L)1 alone has never been proven</h3><p>Let&#8217;s start with the most immunosensitive tumor type: melanoma. Even in the <a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2407417">CheckMate 067 trial</a>, <strong>upfront</strong> &#8220;ipi-nivo&#8221; has not been formally shown to be superior to nivolumab alone in terms of overall survival. This is explained <strong><a href="https://www.drugdevletter.com/p/immune-checkpoint-inhibitors-10-year">here</a></strong>, and summarized in the slide below. </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!qQP9!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!qQP9!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 424w, https://substackcdn.com/image/fetch/$s_!qQP9!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 848w, https://substackcdn.com/image/fetch/$s_!qQP9!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 1272w, https://substackcdn.com/image/fetch/$s_!qQP9!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!qQP9!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png" width="1456" height="816" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:816,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!qQP9!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 424w, https://substackcdn.com/image/fetch/$s_!qQP9!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 848w, https://substackcdn.com/image/fetch/$s_!qQP9!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 1272w, https://substackcdn.com/image/fetch/$s_!qQP9!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F17f199fc-c4ad-4f1c-a10f-7f2177723162_3018x1692.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>In other tumor types, excluding melanoma, 2 meta-analyses have shown no overall survival benefit of the combination over nivolumab alone (<a href="https://jamanetwork.com/journals/jamaoncology/fullarticle/2809043">Serritella and Shenoy</a>, <a href="https://link.springer.com/article/10.1186/s43046-024-00218-2">Rangwala et al.</a>). </p><p><strong>To be clear, dual immunotherapy may still represent an effective strategy in selected settings</strong>, for instance in patients progressing after first-line anti-PD(L)1 monotherapy in melanoma. In other tumour types, dual checkpoint inhibition has also demonstrated benefit when compared with control arms other than anti-PD(L)1 monotherapy, such as tyrosine kinase inhibitors in renal-cell carcinoma.</p><blockquote><p><strong>However, in patients with no prior exposure to immunotherapy, the evidence base to date does not support a survival benefit with dual immunotherapy alone over anti-PD(L)1 monotherapy alone in any tumour type.</strong></p></blockquote><h3>The DART trial only reinforces our concerns</h3><p>The <a href="https://www.annalsofoncology.org/article/S0923-7534(26)00142-0/abstract">DART/SWOG S1609 trial</a> was a large phase 2 trial testing ipilimumab (lower dose of 1 mg/kg every 6 weeks) plus nivolumab across many rare cancers. Overall response rate (ORR) was the primary endpoint. The trial took 6 years to enroll 727 patients into multiple rare tumour cohorts. The signal was heterogeneous: more than half of the cohorts had no clinical activity as defined in the trial, while other rare tumour types showed meaningful activity. Across all patients, the median ORR was only 12 %.</p><p>While dual checkpoint inhibition had significant activity in some groups, the specific contribution of ipilimumab beyond nivolumab in DART remains unknown: <strong>the vast majority of patients (95%) had not received prior anti-PD-(L)1 therapy.</strong></p><h4>Physical toxicity</h4><blockquote><p><strong>A key concern with dual immunotherapy is toxicity. </strong></p></blockquote><p>Immune-related adverse events are very different from those occurring with chemotherapy or oral inhibitors. They can affect any organ, and when high-grade, often requires weeks of corticosteroids. Immune-related toxicity can induce <a href="https://www.nature.com/articles/s41571-022-00600-w">long-lasting impairment</a>, with a potential impact on <a href="https://www.jclinepi.com/article/S0895-4356(21)00221-3/fulltext">quality of life</a>. </p><p>Again in melanoma, the 10-year follow-up data from the <a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2407417">CheckMate 067 trial</a> showed a 63% grade 3-4 rate in patients receiving ipi-nivo, as compared with 25% with nivolumab alone. </p><p>The dose used in CheckMate 067 was 3 mg/kg every 3 weeks for 4 cycles. A lower dose, 1 mg/kg, is known to be less toxic, however, still significantly higher as compared with anti-PD(L)1 monotherapy. </p><blockquote><p><strong>In DART, using the low dose of ipilimumab (1 mg/kg every 6 weeks), grade 3&#8211;4 treatment-related adverse events were reported in 39.2% of patients. Moreover, treatment-related deaths occurred in 1.8% of patients.</strong> </p></blockquote><p>Here is a summary of the <a href="https://www.annalsofoncology.org/article/S0923-7534(26)00142-0/abstract">DART/ SWOG S1609 trial</a> results: </p><ul><li><p>prospective trials are feasible in rare cancers, and this should be commended</p></li><li><p>more than half of cohorts (54.7%) showed no clinical activity</p></li><li><p>overall response rate = 12%</p></li><li><p>unknown contribution beyond anti-PD(L)1 alone (with 95% of patients with no prior exposure)</p></li><li><p>grade 3-4 toxicities = 39.2%</p></li><li><p>treatment-related deaths = 1.8%</p></li></ul><p><strong>As such, we reach different conclusions and disagree that the DART trial supports a broad reimbursement for dual immunotherapy. Rather, we believe it reinforces our concerns.</strong></p><h4>Financial impact of the reimbursement decision</h4><blockquote><p>We noted that in Australia: <strong>&#8220;The projected expenditure associated with this decision is substantial, exceeding AU$1&#8239;billion, with an estimated AU$100&#8211;200&#8239;million attributable to use beyond existing indications. Funding commitments of this magnitude inevitably carry opportunity costs within a fixed health&#8209;care budget, as resources allocated to one intervention are unavailable for alternative health programmes that may deliver greater population&#8209;level benefit.&#8221;</strong></p></blockquote><h3>One way forward: a biomarker-driven strategy together with informed data collection </h3><p>In the Netherlands, the DRUP trial is an adaptive platform trial that provides off-label access to approved targeted therapies and immunotherapies for patients with advanced cancers lacking standard treatment options, while also generating evidence. </p><p>Last month, results were published reporting on 1,610 patients within <a href="https://www.nature.com/articles/s41586-026-10405-x">DRUP</a>, who were treated with 37 different off-label targeted or immunotherapies matched to their molecular profile. The report shows that while clinical benefit was seen in some biomarker-defined subgroups, the overall objective response rate (ORR) was only 16%. </p><blockquote><p>The DRUP investigators recommended that: <strong>&#8220;To maximize patient benefit, [&#8230;] off-label precision medicines should be used only within frameworks that systematically evaluate efficacy and toxicity, support biomarker refinement and enable stepwise assessment toward potential future label expansion.&#8221; </strong></p><p><strong>If anything, the conclusion of the DART trial, with a lower ORR than DRUP, should also be that such off-label use requires systematic outcome collection.</strong></p></blockquote><p>It is therefore important that reimbursement decisions that are not backed by clinical evidence, but are instead primarily motivated by addressing unmet need, are accompanied by structured data collection and planned re-assessments. Otherwise, as a health system, you can never know whether you are helping or harming patients. On one hand, you may expose your target population to unnecessary toxicities, and on the other hand, divert healthcare resources away from other patients. <strong>In this case, the use of a combination therapy is only justified if monotherapy is not sufficiently effective and this requires use in a trial setting and structured data generation.</strong></p><p>Check out our full manuscript for more insights! (<strong><a href="https://www.ejcancer.com/article/S0959-8049(26)00566-6/fulltext">openly available here</a></strong>)</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[RASolute 302 (daraxonrasib) in metastatic pancreatic cancer: a revolution? ]]></title><description><![CDATA[A pharmacological breakthrough might not always revolutionize patients' outcomes.]]></description><link>https://www.theoncologyshot.com/p/rasolute-302-daraxonrasib-in-metastatic</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/rasolute-302-daraxonrasib-in-metastatic</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Mon, 04 May 2026 21:02:13 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!lKG0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>On April 13, 2026, the company Revolution Medicines announced the positive results of the phase 3  trial RASolute 302 in pancreatic cancer via a press-release (<a href="https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/">here</a>). The trial was a multicenter global phase 3 trial, conducted in the US, France, Germany, Italy, Japan, Puerto Rico and Spain (see <a href="https://clinicaltrials.gov/study/NCT06625320#contacts-and-locations">here</a>). It included patients with <strong>metastatic pancreatic cancer</strong> who had <strong>previously received one prior line</strong>, in the metastatic setting, of therapy with 5-fluorouracil (5-FU) based or gemcitabine-based regimen.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!lKG0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!lKG0!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 424w, https://substackcdn.com/image/fetch/$s_!lKG0!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 848w, https://substackcdn.com/image/fetch/$s_!lKG0!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 1272w, https://substackcdn.com/image/fetch/$s_!lKG0!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!lKG0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png" width="1456" height="775" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:775,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1276502,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/194163090?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!lKG0!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 424w, https://substackcdn.com/image/fetch/$s_!lKG0!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 848w, https://substackcdn.com/image/fetch/$s_!lKG0!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 1272w, https://substackcdn.com/image/fetch/$s_!lKG0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa8687950-cd01-48a5-a29d-8a64bfe2be87_1759x936.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong>In RASolute 302</strong>, patients either received <strong>daraxonrasib</strong>, an oral RAS(ON) multi-selective, non-covalent inhibitor; <strong>or chemotherapy</strong>. </p><blockquote><p><strong>More than 90% of patients with metastatic pancreatic cancer have a RAS mutation with about 85% carrying a KRAS G12 mutation. </strong>Contrary to other KRAS inhibitors, daraxonrasib inhibits the active RAS(ON) form. Even RAS-wild-type tumors may be dependent on RAS activation, which is the rationale for investigating daraxonrasib beyond RAS-mutant populations. </p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!VB1F!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!VB1F!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 424w, https://substackcdn.com/image/fetch/$s_!VB1F!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 848w, https://substackcdn.com/image/fetch/$s_!VB1F!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 1272w, https://substackcdn.com/image/fetch/$s_!VB1F!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!VB1F!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png" width="1000" height="650" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/b9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:650,&quot;width&quot;:1000,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:240174,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/194163090?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!VB1F!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 424w, https://substackcdn.com/image/fetch/$s_!VB1F!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 848w, https://substackcdn.com/image/fetch/$s_!VB1F!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 1272w, https://substackcdn.com/image/fetch/$s_!VB1F!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb9febf69-ea51-41fa-821b-fc069306bd5b_1000x650.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><blockquote><p>The press-release says: <strong>&#8220;In the overall (intent-to-treat) study population, daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p &lt; 0.0001). Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.&#8221;</strong></p></blockquote><p>The results will be presented in a few weeks, during <a href="https://www.asco.org/abstracts-presentations/268016">ASCO2026 plenary session</a>, and a simultaneous publication in the <em>New England Journal of Medicine</em> would not be surprising. <br><br>Most doctors, scientists, and academics <strong>agree that we should not practice medicine by press release</strong>. However, following the RASolute 302 press release, social media and the press have echoed the results, mostly within a one-sided framing and an abundance of superlatives, presenting daraxonrasib as a &#8220;miracle&#8221; or a &#8220;revolution.&#8221;</p><p>While doubling median survival in patients with such a poor prognosis is highly unusual, caution is warranted when interpreting any results. Here are some initial thoughts, and what I think we should be looking for during ASCO.</p><h3>Medicine by press-release? Why this is problematic. </h3><p>If we look at the toxicity data for daraxonrasib given as monotherapy, as in RASolute 302, data from patients with advanced pancreatic cancer treated in the phase 1/1b study were reported in a previous Revolution Medicines <a href="https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-provides-clinical-updates-its-rason">press-release</a> issued in December 2024 (screenshot).</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!fkRK!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!fkRK!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 424w, https://substackcdn.com/image/fetch/$s_!fkRK!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 848w, https://substackcdn.com/image/fetch/$s_!fkRK!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 1272w, https://substackcdn.com/image/fetch/$s_!fkRK!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!fkRK!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png" width="1456" height="376" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/cc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:376,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:162629,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/194163090?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!fkRK!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 424w, https://substackcdn.com/image/fetch/$s_!fkRK!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 848w, https://substackcdn.com/image/fetch/$s_!fkRK!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 1272w, https://substackcdn.com/image/fetch/$s_!fkRK!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fcc9451c0-58f4-41bf-ac36-d798cc23d7c1_1890x488.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p><strong>A</strong> <strong>quick read gives the false impression that there is minimal grade 3 or higher treatment-related toxicity</strong>. </p><blockquote><p><strong>This wording indicates that no individual adverse event exceeded 10% of patients. What is missing from the press-release is that, when taken together, approximately 34% of patients in the 300 mg cohort experienced grade 3 or higher treatment-related adverse events (see below). </strong></p></blockquote><p><strong>In other words, this does not mean low toxicity, but rather distributed toxicity.</strong></p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!cgdC!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!cgdC!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 424w, https://substackcdn.com/image/fetch/$s_!cgdC!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 848w, https://substackcdn.com/image/fetch/$s_!cgdC!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 1272w, https://substackcdn.com/image/fetch/$s_!cgdC!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!cgdC!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp" width="800" height="651" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:651,&quot;width&quot;:800,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:&quot;Shaalan Beg: Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic?&quot;,&quot;title&quot;:&quot;Shaalan Beg: Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? 2&quot;,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="Shaalan Beg: Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic?" title="Shaalan Beg: Is 2025 going to be the year Pan-RAS inhibitors make it into the clinic? 2" srcset="https://substackcdn.com/image/fetch/$s_!cgdC!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 424w, https://substackcdn.com/image/fetch/$s_!cgdC!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 848w, https://substackcdn.com/image/fetch/$s_!cgdC!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 1272w, https://substackcdn.com/image/fetch/$s_!cgdC!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F732750a4-ed21-4d3a-9380-37bb41466045_800x651.webp 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Slide presented at <a href="https://dailynews.ascopubs.org/do/pan-ras-inhibitor-shows-early-deep-molecular-responses-pdac">ASCO GI 2025</a>.</figcaption></figure></div><p>Toxicity data will be much awaited from the ASCO 2026 presentation. We can already get a glimpse of how <strong>&#8220;nasty&#8221;</strong> the drug can be. Here, I&#8217;m quoting Senator Ben Sasse, who has publicly shared his personal story after being diagnosed with advanced pancreatic cancer and enrolling in RASolute 302.</p><blockquote><p>Ben Sasse : <strong>&#8220;I take it orally, but it&#8217;s a nasty drug. It causes crazy stuff like my body can&#8217;t grow skin and so I bleed all out of a whole bunch of parts of me that shouldn&#8217;t be bleeding.&#8221;</strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!8Mzn!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!8Mzn!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 424w, https://substackcdn.com/image/fetch/$s_!8Mzn!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 848w, https://substackcdn.com/image/fetch/$s_!8Mzn!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 1272w, https://substackcdn.com/image/fetch/$s_!8Mzn!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!8Mzn!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png" width="1356" height="854" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:854,&quot;width&quot;:1356,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1145851,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/194163090?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!8Mzn!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 424w, https://substackcdn.com/image/fetch/$s_!8Mzn!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 848w, https://substackcdn.com/image/fetch/$s_!8Mzn!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 1272w, https://substackcdn.com/image/fetch/$s_!8Mzn!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F5354c2b3-7f7b-4740-a505-3ddfe5a80b81_1356x854.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">From an interview published in the New York Times on April 9, 2026 (<a href="https://www.nytimes.com/2026/04/09/opinion/ben-sasse-death-pancreatic-cancer.html">link here</a>)</figcaption></figure></div><p>Former Senator Ben Sasse has given numerous interviews describing what he is going through as a patient with advanced pancreatic cancer. He has explicitly mentioned pain reduction and significant tumor shrinkage, and noted that &#8220;this experience has seemingly extended both quantity and quality of life&#8221; (<a href="https://www.statnews.com/2026/04/14/ben-sasse-revolution-medicines-daraxonrasib-clinical-trial/">here</a>). At the same time, his public appearances and recounting also highlight the significant toxicities associated with the treatment.</p><blockquote><p>So when we come back to the most recent press release from Revolution Medicine: <strong>&#8220;Daraxonrasib was generally well tolerated, with a manageable safety profile and with no new safety signals.&#8221;</strong> I wonder if patients, including Ben Sasse, would find that this wording is accurately reflecting his and other patients&#8217; general experience. </p></blockquote><h3>Medicine by press-release? If we have no choice, let&#8217;s do it!<br></h3><p>Let&#8217;s gather data from the <strong><a href="https://ir.revmed.com/news-releases/news-release-details/daraxonrasib-demonstrates-unprecedented-overall-survival-benefit/">press-release</a></strong> and from <strong><a href="https://clinicaltrials.gov/study/NCT06625320">clinicaltrials.gov</a></strong>, and let&#8217;s see what we can make of it: </p><ul><li><p>the trial included <strong>500 patients</strong>, unselected for specific RAS mutations</p></li><li><p><strong>primary endpoints</strong> = PFS and OS <strong>in RAS-G12-mutant patients</strong></p></li><li><p><strong>secondary endpoints</strong> = OS and PFS <strong>in all patients </strong></p></li><li><p>&#8220;Trial <strong>met all primary and key secondary endpoints</strong>, including progression-free survival and overall survival&#8221;</p></li><li><p><strong>&#8220;In the overall (intent-to-treat) study population, daraxonrasib demonstrated a median OS of 13.2 months versus 6.7 months for chemotherapy, with a hazard ratio of 0.40 (p &lt; 0.0001).&#8221;</strong></p></li><li><p>Study start (first patient): <strong>October 16, 2024; </strong>Enrollment (500 patients) completed: <strong>at least in December 2025; </strong>Total accrual duration: <strong>maximum 14 months; </strong>Press release 13 April 2026 (data-cut off likely in March 2026); Maximum follow-up duration about 17 months</p></li></ul><blockquote><p><strong>The headline OS result is based on a secondary endpoint in the broadest patient population, while the primary endpoints, PFS and OS in the KRAS G12-mutant population, remain unreported</strong></p></blockquote><h3>Why the OS estimates in the entire population could be overestimated. </h3><p>Several factors may have contributed to an inflation of the reported results.</p><ol><li><p><strong>Power</strong> is usually calculated for the primary endpoint(s). As such, OS in the ITT population may be insufficiently powered. Additionally, <strong>hierarchical testing</strong> can reduce the <strong>available alpha</strong>, effectively reducing power in the ITT analysis.</p></li><li><p><strong>Nested </strong><em><strong>versus</strong></em><strong> adjacent subgroups</strong> <a href="https://pubmed.ncbi.nlm.nih.gov/34388514/">analyses</a>. As the primary endpoints are in the RAS G12-mutant population, one key question for the overall population is: are non&#8211;G12 RAS-mutant patients truly deriving benefit, or is the observed effect in the &#8220;overall population&#8221; mainly driven by the G12-mutant population?</p></li><li><p><strong>Early stopping rules </strong>carry a risk of inflating effect estimates, as shown in <a href="https://jamanetwork.com/journals/jama/article-abstract/201802">empirical work</a>. Were such rules used in RASolute 302? </p></li><li><p><strong>Efficacy&#8211;effectiveness gap?</strong> Patients in clinical trials often do not reflect real-world patients, who typically derive less benefit and may experience more toxicity. This is referred to as the efficacy&#8211;effectiveness gap. Even if the reported survival benefit is considered reliable, how it will translate into real-world practice remains an open question.</p></li></ol><h3>Longer follow-up matters: the NAPOLI-1 example. </h3><p>Will <strong>longer follow-up</strong> data will ultimately be made available. The question is real, as the results are presented as being <a href="https://www.asco.org/abstracts-presentations/268016">&#8220;primary and final&#8221;</a>. </p><p>To illustrate the effect of longer follow-up, here is the NAPOLI-1 trial as an example, where we have two data points from the 2016 and 2019 reports. NAPOLI-1 was conducted in a setting comparable to RASolute 302. As shown in the estimations below, with longer follow-up, an early separation tends to diminish, with a less pronounced statistical gain.</p><blockquote><p><strong>This illustrates how early apparent benefit may attenuate with longer follow-up</strong>.</p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!mrHZ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!mrHZ!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 424w, https://substackcdn.com/image/fetch/$s_!mrHZ!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 848w, https://substackcdn.com/image/fetch/$s_!mrHZ!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 1272w, https://substackcdn.com/image/fetch/$s_!mrHZ!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!mrHZ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png" width="1456" height="727" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:727,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:498006,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/194163090?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!mrHZ!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 424w, https://substackcdn.com/image/fetch/$s_!mrHZ!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 848w, https://substackcdn.com/image/fetch/$s_!mrHZ!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 1272w, https://substackcdn.com/image/fetch/$s_!mrHZ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F9d7bfe80-280a-493c-aa7c-274c7d785b2c_2974x1484.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Both trials&#8217; reconstructed curves are available <a href="https://www.timotheeolivier-research.com/breaking-ice">here</a> (select NAPOLI-1 trials)</figcaption></figure></div><h3>Key questions for ASCO and the full publication</h3><ul><li><p>Statistical details: <strong>early stopping rules</strong> if specified, <strong>alpha spending</strong> for each endpoint (particularly the ITT secondary endpoints), n<strong>umber of interim analyses planned</strong>, etc.</p></li><li><p>What is the <strong>median follow-up</strong> and <strong>OS maturity</strong>, what about <strong>censoring</strong>?</p></li><li><p>The <strong>shape of Kaplan&#8211;Meier curves</strong>: early separation ? curve crossing ? any tail?</p></li><li><p><strong>ITT vs primary endpoints population</strong>: how much of the OS benefit in the entire ITT population may have been driven by the prespecified RAS-G12 population </p></li><li><p><strong>Is the objective response rate (ORR) maintained?</strong> In the phase 1/1b study, the confirmed ORR was 35% in the RAS G12 population and 29% in the overall population. Classically, ORR tends to decrease from early-phase to later-stage studies. As a reminder, sotorasib (a KRAS G12C inhibitor) had an ORR of 37.1% in the early-phase CodeBreaK 100 trial, which later decreased to 28.1% in CodeBreaK 200.</p></li><li><p><strong>Toxicity data!</strong> </p></li><li><p><strong>Quality of life data</strong>: if presented: how and when they were measured, compliance rate, timing of measurements, etc. </p></li></ul><h3>Long-term efficacy? Drugs facing cancer biology</h3><p>In 2011, <a href="https://connection.asco.org/do/challenge-and-promise-genomic-era-presidential-address-george-sledge-md">George Sledge</a> highlighted that the genomic era could bring both promise and chaos. He distinguished <strong>&#8220;stupid&#8221; cancers</strong>, like those driven by a single driver mutation, such as chronic myeloid leukemia (CML). In these settings, inhibitors can be transformative: in CML, life expectancy became <a href="https://pubmed.ncbi.nlm.nih.gov/27325849/">comparable to the general population after the introduction of imatinib</a>.</p><p>Yet, most solid tumors are different. They rarely rely on a single driver, and instead harbor co-mutations and <a href="https://www.nature.com/articles/s41586-026-10428-4">multiple clones</a>. <strong>In advanced disease, resistance at some point is the rule rather than the exception.</strong> Although daraxonrasib does not target a single mutation but rather RAS across multiple contexts, advanced pancreatic cancer remains a biologically <strong>&#8220;smart&#8221; cancer</strong>. </p><p>To which extent a broad RAS(ON) inhibition can temporarily suppress the genomic and adaptive complexity that usually drives resistance in pancreatic cancer is unclear. </p><h3>My (temporary) conclusion.</h3><p>Even though I&#8217;m awaiting for the data, I see daraxonrasib as a pharmacological breakthrough, however associated with significant toxicities and inherent biological hurdles when it comes to long-term efficacy. </p><p>On social media, discussions have at times become emotional, with any critical appraisal of a trial being perceived as a lack of empathy, which is unfortunate. We should not forget that <a href="https://www.wsj.com/finance/investing/theres-a-revolution-in-cancer-but-can-big-pharma-afford-it-56dda49d">financial stakes are high</a>. Personal stories should not replace careful interpretation of the data.</p><p>In oncology, we often say a drug should help patients live longer and/or better. In the case of daraxonrasib, even with a survival benefit, the toxicity profile and the uncertainty around long-term benefit may make the choice not as straightforward for a fraction of patients. </p><div><hr></div><blockquote><p><strong>Whether a treatment that delays, but does not prevent, death, while adding significant toxicity, constitutes a &#8220;revolution&#8221; is a question best answered by patients, not by Key Opinion Leaders (KOLs) or companies.</strong></p></blockquote><p></p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[An Eagle Eye on AQUILA Survival Data. Our New Paper Is Out. IQWiG Wins, OpenEvidence Fails.]]></title><description><![CDATA[Our new paper, with Sunny Kim and Vinay Prasad, is out in the Journal of Cancer Policy and is openly available here! Not all patients with Smoldering Myeloma will progress to Multiple Myeloma, a malignant condition.]]></description><link>https://www.theoncologyshot.com/p/an-eagle-eye-on-aquila-survival-data</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/an-eagle-eye-on-aquila-survival-data</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Tue, 14 Apr 2026 14:15:56 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!yQzf!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>Our new paper, with <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Sunny Kim&quot;,&quot;id&quot;:16161205,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:null,&quot;uuid&quot;:&quot;d819239d-db5a-4f9e-bf38-ef4e0bc83d9d&quot;}" data-component-name="MentionToDOM"></span> and <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Vinay Prasad&quot;,&quot;id&quot;:21798998,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:&quot;https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8d9b3de5-2e57-4d32-a0d4-99f8431caa20_8688x5792.jpeg&quot;,&quot;uuid&quot;:&quot;7e6f9169-f0c8-45d8-82f4-ee359c98c0a8&quot;}" data-component-name="MentionToDOM"></span>, is out in the <em>Journal of Cancer Policy</em> and is openly available <strong><a href="https://www.sciencedirect.com/science/article/pii/S2213538326000378">here</a>!</strong> Not all patients with <strong>Smoldering Myeloma</strong> will progress to <strong>Multiple Myeloma</strong>, a malignant condition. Since many years, we knew that daratumumab (or other anti-CD38 therapies) are part of the best standard of care for patients with multiple myeloma. Such compounds are now commonly used as part of the first-line therapy. </p><blockquote><p><strong>In this new publication, we review if the current evidence support the use of systemic therapy in high-risk Smoldering Myeloma, or if observation should remain the standard (which is, spoiler, our conclusion). </strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!yQzf!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!yQzf!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 424w, https://substackcdn.com/image/fetch/$s_!yQzf!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 848w, https://substackcdn.com/image/fetch/$s_!yQzf!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 1272w, https://substackcdn.com/image/fetch/$s_!yQzf!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!yQzf!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png" width="1456" height="795" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/d8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:795,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:814421,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/193901658?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!yQzf!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 424w, https://substackcdn.com/image/fetch/$s_!yQzf!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 848w, https://substackcdn.com/image/fetch/$s_!yQzf!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 1272w, https://substackcdn.com/image/fetch/$s_!yQzf!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fd8dd52a1-1ffd-4b1d-a16d-c018f553cd51_2916x1592.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>The AQUILA trial was a global, open-label trial, that tested whether patients with <strong>high-risk Smoldering Myeloma</strong> should receive <strong>daratumumab</strong> (for up to 36 months) or <strong>active surveillance</strong>. The primary endpoint was Progression-Free Survival, Overall Survival (OS) was a secondary endpoint. </p><p>AQUILA was published in the <em><a href="https://www.nejm.org/doi/abs/10.1056/NEJMoa2409029">New England Journal of Medicine</a></em>, and showed an improvement in PFS in patients allocated to receive daratumumab (HR = 0.49; 95% CI, 0.36&#8211;0.67; P&lt;0.001), with 5-year progression-free survival of 63.1% versus 40.8% with active monitoring. <br><br>The trial also report an <strong>overall survival difference favoring daratumumab</strong> (HR = 0.52; 95% CI, 0.27&#8211;0.98), and the trial led to the approval by both the FDA and the EMA, and its inclusion as a Category 1 option in the NCCN guidelines for high-risk smoldering myeloma.</p><blockquote><p>The survival difference observed in AQUILA has been cited as a reason that this study should change the standard of care to treat all patients with high-risk smoldering myeloma. This is the reason why we focus today on survival data. <strong>Our overall conclusion is simple: observation with appropriate surveillance should remain the standard-of-care in high-risk smoldering myeloma.</strong></p></blockquote><h2>Key Subsequent Data, once again brought to us exclusively by IQWiG!</h2><p>From the seminal publication, we knew that 105 patients in the control group received at least one subsequent therapy, and that 35 patients received daratumumab or another anti-CD38 compound as part of their <strong>first-line therapy</strong>. Even though this number was low (33.3% of patients receiving subsequent systemic therapy), some could have contend that daratumumab or other anti-CD38 therapy could have been given later in the course of the disease: <strong>this piece of data was, to date, unreported</strong>.  </p><p>However, as highlighted in a <a href="https://www.theoncologyshot.com/p/an-outstanding-source-of-trial-data">previous post</a>, the german Health Technology Assessment body, <strong>IQWiG</strong> (Institut f&#252;r Qualit&#228;t und Wirtschaftlichkeit im Gesundheitswesen), is requiring granular subsequent therapy data to be provided by sponsors, and are making their assessments publicly available. </p><blockquote><p>Based on their February 2026 report (available <a href="https://www.iqwig.de/download/a25-109_daratumumab_nutzenbewertung-35a-sgb-v_v1-0.pdf">here</a>), we now know that <strong>&#8220;a maximum number of 61 (58%) patients (&#8230;) received subsequent therapy with CD38 antibodies, regardless of the line of therapy.&#8221;</strong></p></blockquote><p>As a result, at least 44 control group patients 1) progressed,  2) received a subsequent therapy, and 3) were never exposed to daratumumab or other anti-CD38 therapy at any time. These patients are making at least 22.4% of control arm patients. Even though we still don&#8217;t know how many patients died without ever receiving daratumumab, this key metric provide important context. On the figure below, the absolute difference in 5-year survival is contextualized with this metric: </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!X8iq!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!X8iq!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 424w, https://substackcdn.com/image/fetch/$s_!X8iq!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 848w, https://substackcdn.com/image/fetch/$s_!X8iq!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 1272w, https://substackcdn.com/image/fetch/$s_!X8iq!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!X8iq!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png" width="1456" height="889" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:889,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:503051,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/193901658?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!X8iq!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 424w, https://substackcdn.com/image/fetch/$s_!X8iq!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 848w, https://substackcdn.com/image/fetch/$s_!X8iq!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 1272w, https://substackcdn.com/image/fetch/$s_!X8iq!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F864b9aa3-5a5e-4c0b-b714-d2d1f717aed3_2466x1506.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><blockquote><p><strong>To my knowledge, this key metric reported in the IQWiG report is not available elsewhere, highlighting the unique value of their work and reports.</strong></p></blockquote><h3>OpenEvivence failed: do not rely on AI tools for appraising the data</h3><p>There is major enthusiam about new AI tools, which I partly share, in particular for coding. A recent trend concerns the value of <a href="https://www.openevidence.com/">OpenEvidence</a>, a platform which is officially partnering with journals like the <em>New England Journal of Medicine</em> or <em>JAMA</em>. </p><p>Logically, you would expect a <em>New England Journal of Medicine</em> publication like AQUILA to be accurately summarized. Yet, on April 11, 2026, while reviewing the proofs of our work, I tested OpenEvidence. Here is a copy paste of my &#8220;conversation&#8221;.</p><blockquote><p><strong>&#8220;Could you please provide me the summary of the overall survival results from AQUILA ?&#8221;</strong></p></blockquote><p>OpenEvidence:</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!vARJ!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!vARJ!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 424w, https://substackcdn.com/image/fetch/$s_!vARJ!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 848w, https://substackcdn.com/image/fetch/$s_!vARJ!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 1272w, https://substackcdn.com/image/fetch/$s_!vARJ!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!vARJ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png" width="1456" height="752" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:752,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:559456,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/193901658?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!vARJ!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 424w, https://substackcdn.com/image/fetch/$s_!vARJ!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 848w, https://substackcdn.com/image/fetch/$s_!vARJ!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 1272w, https://substackcdn.com/image/fetch/$s_!vARJ!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F1f32f3ce-3968-438d-a869-1b6d1982abac_1940x1002.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><blockquote><p><strong>Me pushing back: &#8220;But I don&#8217;t understand, you say it was statistically significant, however in the hierarchical testing, it should only be tested after ORR and PFS2 no ? And PFS2 results are not reported, nor is the p-value for OS ?&#8221;</strong></p></blockquote><p>OpenEvidence:</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!eqA0!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!eqA0!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 424w, https://substackcdn.com/image/fetch/$s_!eqA0!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 848w, https://substackcdn.com/image/fetch/$s_!eqA0!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 1272w, https://substackcdn.com/image/fetch/$s_!eqA0!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!eqA0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png" width="1456" height="1399" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1399,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:929912,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/193901658?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!eqA0!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 424w, https://substackcdn.com/image/fetch/$s_!eqA0!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 848w, https://substackcdn.com/image/fetch/$s_!eqA0!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 1272w, https://substackcdn.com/image/fetch/$s_!eqA0!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F47bd3ebf-f25b-4794-8093-b160274e42f5_1698x1632.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><blockquote><p>This example is not trivial. <strong>Many think OpenEvidence accurately summarizes key data from seminal trials, and here it failed to do so with the survival data from a trial that could affect thousands of patients worldwide</strong>. <strong>My take: do not be dependent on AI tools. If the computer shuts down, you should still be able to talk to your patients.</strong></p></blockquote><h3>Informative censoring in survival data? Likely.</h3><p>We noted an imbalance in censoring rates for both PFS <strong>and</strong> OS. It is plausible that patients dropping out in excess from the control arm were healthier, more connected, seeking for active therapy outside the trial, and had a lower-risk of event as compared to patients remaining in the control arm. Those patients, had they stayed, could have been late censored (at data-cutoff) instead of being early censored. This is called <strong>&#8220;disappointement-driven informative censoring&#8221;</strong>.</p><p>In AQUILA, we generated <strong>pseudo-Individual Patient Data</strong> and, using the <a href="https://drive.google.com/file/d/1Oq6lNM__0qMAIMHCRj5D8LtYA8QFcZsb/view">BREAKING-ICE App&#169;</a>, we conducted a sensitivity analysis to determine the minimum number of patients censored over the first 12 months in the control arm whose censoring status would need to be changed from early to late censoring for the confidence interval to cross one. </p><blockquote><p><strong>We found that changing the status of 3 patients was sufficient. Notably, even under this conservative sensitivity analysis, censoring rates at 12 months remained significantly higher in the control group (3.6% vs 0.5%).</strong> </p></blockquote><p>The analysis is openly available <a href="https://www.timotheeolivier-research.com/breaking-ice">here</a> (select &#8220;AQUILA-OS&#8221;), and shown below: </p><div class="native-video-embed" data-component-name="VideoPlaceholder" data-attrs="{&quot;mediaUploadId&quot;:&quot;ffd3c41c-67ed-4739-8146-eae98261caa3&quot;,&quot;duration&quot;:null}"></div><h3>Summary of AQUILA survival data</h3><ol><li><p>an absolute <strong>difference of 6.1% is observed at 5-year</strong></p></li><li><p>this difference is <strong>not formally statistically significant</strong></p></li><li><p><strong>likely driven by suboptimal subsequent therapy</strong> in control group patients (22.4% received a subsequent therapy without ever being exposed to an anti-CD38 therapy; how many patients died without ever receiving datatumumab?)</p></li><li><p><strong>likely driven by informative censoring</strong></p></li></ol><h3>Observation should remain standard-of-care, and this is actually in line with NCCN guidelines!</h3><p>Based on the survival data, as well as many other aspects, we conclude that <strong>&#8220;observation including appropriate surveillance should remain the standard of care for high-risk smoldering multiple myeloma.&#8221;</strong></p><p>Interestingly, it should be noted that <strong>a category 1 NCCN guidelines recommendation does not imply a preferred option</strong>. Here is a screenshot from Version 5.2026 NCCN guidelines where panelists do not recommend systemic therapy as the preferred option. </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!GPL8!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!GPL8!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 424w, https://substackcdn.com/image/fetch/$s_!GPL8!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 848w, https://substackcdn.com/image/fetch/$s_!GPL8!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 1272w, https://substackcdn.com/image/fetch/$s_!GPL8!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!GPL8!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png" width="1456" height="497" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:497,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:197282,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/193901658?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!GPL8!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 424w, https://substackcdn.com/image/fetch/$s_!GPL8!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 848w, https://substackcdn.com/image/fetch/$s_!GPL8!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 1272w, https://substackcdn.com/image/fetch/$s_!GPL8!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F29df2f08-8c4a-4a44-acf8-22c3df689a6b_1624x554.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Check-out our <strong>full paper for more insights (<a href="https://www.sciencedirect.com/science/article/pii/S2213538326000378">here</a>)</strong>. See also the recent video on this topic with <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Rajshekhar Chakraborty&quot;,&quot;id&quot;:49354983,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:&quot;https://bucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com/public/images/8fb9bcd8-a4a5-4660-abb4-7e4460c1d828_144x144.png&quot;,&quot;uuid&quot;:&quot;e21de4a1-d5d9-4d94-a17b-a57bdbbc3672&quot;}" data-component-name="MentionToDOM"></span> <a href="https://www.theoncologyshot.com/p/an-interview-with-professor-rajshekhar">here</a>!</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p><p></p>]]></content:encoded></item><item><title><![CDATA[The Chinese Immunotherapy That Passed the Dutch Test, and How To Assess What is Expected to Be a Tsunami of Immunotherapies. ]]></title><description><![CDATA[The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse.]]></description><link>https://www.theoncologyshot.com/p/the-chinese-immunotherapy-that-passed</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/the-chinese-immunotherapy-that-passed</guid><dc:creator><![CDATA[Sahar van Waalwijk]]></dc:creator><pubDate>Sun, 12 Apr 2026 12:01:53 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!BsS4!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>The Dutch are rather picky in selecting which oncology drugs to prescribe or reimburse. They use a set of criteria called <a href="https://www.nvmo.org/over-de-adviezen/">PASKWIL</a> to define what is clinically meaningful. Recently, the Dutch have been quite excited about serplulimab, an immunotherapy developed in China. </p><blockquote><p><strong>It is the first immunotherapy for extensive-stage small-cell lung cancer (ES-SCLC) to meet the PASKWIL criteria.</strong></p></blockquote><p>This drug is offered on its <a href="https://int.haiouhealth.com/drugs/serplulimab/price/613.html">website in China</a> for US$290 per vial, yet in Europe it costs roughly 5.5 times more. You might think that this is due to the effort of making the drug relevant for the European market. But no&#8230; there were in total only 7 European patients recruited in the trial. The <a href="https://www.ema.europa.eu/en/documents/assessment-report/hetronifly-epar-public-assessment-report_en.pdf">effects</a> of the drug are also rather modest: in combination with chemotherapy, it delays progression or death by about 1.4 months compared with chemotherapy alone. And the median overall survival benefit is 4.5 months (HR 0.63, 95% CI: 0.49&#8211;0.82).</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!BsS4!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!BsS4!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 424w, https://substackcdn.com/image/fetch/$s_!BsS4!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 848w, https://substackcdn.com/image/fetch/$s_!BsS4!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 1272w, https://substackcdn.com/image/fetch/$s_!BsS4!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!BsS4!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png" width="1456" height="810" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/a84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:810,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:4640810,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/193916382?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!BsS4!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 424w, https://substackcdn.com/image/fetch/$s_!BsS4!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 848w, https://substackcdn.com/image/fetch/$s_!BsS4!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 1272w, https://substackcdn.com/image/fetch/$s_!BsS4!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fa84397a1-373a-4c12-a338-cc7e82b6a810_2978x1656.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><blockquote><p><strong>Today&#8217;s question is simple: although the PASKWIL criteria provide an invaluable framework for evaluating novel indications and therapies, are HTA agencies equipped to assess them when multiple compounds from the same class are tested?</strong></p></blockquote><h2>Most profitable class of drugs</h2><p>It is easy to lose track of how many immunotherapies like serplulimab are currently available. Nivolumab and pembrolizumab were the first to enter the market in 2014 and have since developed the most indications. Currently, there are around 14&#8211;15 or even more me-too versions of these drugs on the market, but this is only the beginning of what is expected to be a tsunami of such agents. </p><blockquote><p><strong>In total, more than <a href="https://www.researchandmarkets.com/reports/5675631/pd-1-and-pd-l1-inhibitors-competitive?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=z8n2wc&amp;utm_campaign=2167517+-+PD-1+and+PD-L1+Inhibitors+Competitive+Landscape+Report+2026%3a+Comprehensive+Insights+on+200%2b+Drugs+from+Over+180+Companies+by+Company%2c+Product+Type%2c+Stage%2c+Route+of+Administration%2c+and+Molecule+Type&amp;utm_exec=chdomsai">180 companies are developing over 200 of these immunotherapies</a>.</strong></p></blockquote><p>The reason for such investments is profitability. Companies have found ways not to compete directly in the market. Studies are often conducted slightly differently, in different indications and settings, or in combination with different agents. We are often led to believe that one drug is slightly better than another for a specific indication based on &#8220;expert opinion&#8221; or the overinterpretation of subgroups or post-hoc analyses; but in fact there is no robust evidence to justify such conclusions. </p><blockquote><p><strong>There are few within-class head-to-head trials, and even fewer showing a survival gain of one compound over the other</strong> (see <a href="https://drive.google.com/file/d/139XBSqMB0CUguO-AV-zLR1zyTiFVotJE/view">here</a>).</p></blockquote><h2>The landscape of immunotherapies for extensive-stage small-cell lung cancer</h2><p>Serplulimab is not the only immunotherapy authorised in Europe for ES-SCLC. Two other immunotherapies, atezolizumab and durvalumab, are also authorised. However, their effect is even smaller, with median overall survival benefits of 2 months (HR 0.76, 95% CI: 0.60&#8211;0.95) and 2.4 months (HR 0.75, 95% CI: 0.63&#8211;0.91), respectively. (See Assessment of the EMA comparing the results <a href="https://www.ema.europa.eu/en/documents/assessment-report/hetronifly-epar-public-assessment-report_en.pdf">here</a>).</p><p><strong>But there is also a history of negative trials.</strong> For instance, KEYNOTE-604, a Phase 3 trial of pembrolizumab plus chemotherapy, failed to meet the overall survival endpoint required for full FDA approval, and its <a href="https://ascopost.com/news/march-2021/pembrolizumabs-indication-in-small-cell-lung-cancer-is-withdrawn/#:~:text=The%20accelerated%20approval%20for%20pembrolizumab,and%20opinions%20of%20ASCO%C2%AE.">accelerated approval was withdrawn</a> for metastatic SCLC in March 2021. Also, nivolumab plus chemotherapy (<a href="https://pubmed.ncbi.nlm.nih.gov/40526078/">EA5161</a>) failed to reach statistical significance versus chemotherapy alone (Figure 1).</p><blockquote><p>To our surprise, no HTA agencies appear to consider these negative trials in their assessments, and thus they may miss the overall picture. Surely, we do not want reimbursement decisions to be based on coincidence or bias. <strong>If one looks at the overall effect of immunotherapies in ES-SCLC, they will not pass the Dutch test.</strong></p></blockquote><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!HTdb!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!HTdb!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 424w, https://substackcdn.com/image/fetch/$s_!HTdb!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 848w, https://substackcdn.com/image/fetch/$s_!HTdb!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 1272w, https://substackcdn.com/image/fetch/$s_!HTdb!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!HTdb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png" width="676" height="742" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/e31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:742,&quot;width&quot;:676,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!HTdb!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 424w, https://substackcdn.com/image/fetch/$s_!HTdb!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 848w, https://substackcdn.com/image/fetch/$s_!HTdb!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 1272w, https://substackcdn.com/image/fetch/$s_!HTdb!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fe31eb272-2f7d-4383-a817-eaab78aec5ce_676x742.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">Figure 1. A comparison of progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) across different trials by <a href="https://tcr.amegroups.org/article/view/89511/html">Chen et al</a>.</figcaption></figure></div><h2>Multiplicity and me-too drug development</h2><p>This introduces the concept of <strong><a href="https://onlinelibrary.wiley.com/doi/10.1111/eci.13802">multiplicity</a></strong> which has emerged with the surge of me-too drug development. <strong>It is not excluded that the same class of agents, tested again and again, will ultimately yield some positive results by chance alone.</strong> In such cases, statistical estimates can be reassessed taking into account multiplicity, using methods like Bonferroni or Stein estimation. </p><p>In a recent work from Carlisle and colleagues focusing on <strong>immune checkpoint-inhibitors trials</strong>, the authors used Stein estimation to account for the crowded trials with me-too compounds. They found that, after adjusting for the totality of trials, estimates of results, in terms of hazard radio, decreased in 35% of trials, and amoung trials with an original p-value that was inferior to 0.05, 27% of those lost significance after adjustment (their work <a href="https://www.sciencedirect.com/science/article/pii/S0895435626000570">here</a>). </p><blockquote><p><strong>In other words, while considering the redundancy of trials in similar class of drugs, it is not excluded that some positive results will be the result of a statistical artifact, which should be accounted for with appropriate methods.</strong></p></blockquote><h2>Reimbursement decisions should consider the totality of evidence</h2><p>In the following scenarios, we use analogies to illustrate how reimbursement decisions are made in practice and how they are intended to be made.</p><ul><li><p><strong>Scenario 1:</strong> Imagine you are standing in a drugstore, looking at different brands of a supplement on the shelf. You read the packaging, compare prices, and then, based on your needs and budget, decide whether to choose one. This is similar to how reimbursement decisions are often made.</p></li><li><p><strong>Scenario 2:</strong> Imagine that, before going to the drugstore, you search PubMed for studies on different variants of that supplement. You realise that the evidence is not straightforward: some studies are positive, while others are negative. In such cases, meta-analyses, systematic reviews, and even statistical approaches accounting for the numerous trials, can help determine whether the overall effect is clinically meaningful for you.</p></li></ul><p>This is essentially what health technology assessors are expected to do. Their role is to consider all available evidence when evaluating a medicine, including negative studies involving the same class of drug for that indication. Without strong HTA, healthcare systems risk funding expensive drugs with little benefit.</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p>]]></content:encoded></item><item><title><![CDATA[An outstanding source of trial data lacking from publications: IQWiG assessment reports. The NIAGARA trial example.]]></title><description><![CDATA[Reports from HTA bodies may contain key data absent from trial publications and constitute a unique source for trial appraisal.]]></description><link>https://www.theoncologyshot.com/p/an-outstanding-source-of-trial-data</link><guid isPermaLink="false">https://www.theoncologyshot.com/p/an-outstanding-source-of-trial-data</guid><dc:creator><![CDATA[Timothée Olivier]]></dc:creator><pubDate>Wed, 25 Mar 2026 11:49:32 GMT</pubDate><enclosure url="https://substackcdn.com/image/fetch/$s_!sOUI!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png" length="0" type="image/jpeg"/><content:encoded><![CDATA[<p>An underappreciated source of trial data, which may be lacking in publications, are public reports from various Health Technology Assessments (HTA) and regulators. Among the numerous and valuable sources, the German HTA body, <strong><a href="https://www.iqwig.de/en/">The Institute for Quality and Efficiency in Healthcare (IQWiG)</a></strong>, is one agency I want to highlight, as they are requiring key aspects of the data to be submitted to their agency and, as a result, you can find those data in their public reports. </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!sOUI!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!sOUI!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 424w, https://substackcdn.com/image/fetch/$s_!sOUI!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 848w, https://substackcdn.com/image/fetch/$s_!sOUI!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 1272w, https://substackcdn.com/image/fetch/$s_!sOUI!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!sOUI!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png" width="1456" height="798" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:798,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:2184246,&quot;alt&quot;:&quot;&quot;,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:true,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/191951866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" title="" srcset="https://substackcdn.com/image/fetch/$s_!sOUI!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 424w, https://substackcdn.com/image/fetch/$s_!sOUI!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 848w, https://substackcdn.com/image/fetch/$s_!sOUI!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 1272w, https://substackcdn.com/image/fetch/$s_!sOUI!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4bb8c564-edb2-4565-ab66-57a91128dc54_2678x1468.png 1456w" sizes="100vw" fetchpriority="high"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3>Where are subsequent therapy data from NIAGARA?</h3><p>In a previous video, I made a side-by-side comparison between NIAGARA and AMBASSADOR trials (<strong>video <a href="https://www.theoncologyshot.com/p/post-protocol-care-the-missing-piece?utm_campaign=post&amp;utm_medium=web&amp;timestamp=1734.0">available here</a></strong>). Both trials were run in the peri-operative setting of bladder cancer (NIAGARA is neo-adjuvant followed by adjuvant, AMBASSADOR is purely adjuvant). Both trials demonstrated an EFS/DFS gain in the experimental arm. Trials&#8217; design (left) and their corresponding EFS/DFS results (right) are shown below: </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!d036!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!d036!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 424w, https://substackcdn.com/image/fetch/$s_!d036!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 848w, https://substackcdn.com/image/fetch/$s_!d036!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 1272w, https://substackcdn.com/image/fetch/$s_!d036!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!d036!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png" width="1456" height="829" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:829,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:1447987,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/191951866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!d036!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 424w, https://substackcdn.com/image/fetch/$s_!d036!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 848w, https://substackcdn.com/image/fetch/$s_!d036!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 1272w, https://substackcdn.com/image/fetch/$s_!d036!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F7063dd5b-40eb-4906-bc5d-188c20c94ba2_2934x1670.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>However, only NIAGARA demonstrated an overall survival gain. The side-by-side comparison was primarily aimed at highlighting that, <strong>in global trials like NIAGARA, a survival gain may be driven by the limited access to optimal care for patients who recur.</strong> </p><blockquote><p>Such limited access is explained when some enrolling countries are simply lacking access to the best care outside the trial. Conversely, in trials like AMBASSADOR, that was exclusively run in the US, optimal access to post-protocol care, which is desirable!, may have explained the absence of survival gain. </p></blockquote><p>In a paper published in the <em>European Journal of Cancer</em> (<strong><a href="https://linkinghub.elsevier.com/retrieve/pii/S0959-8049(25)00484-8">full paper here</a></strong>), we posit that such global trials are rewarded in terms of guideline recommendations and approvals. </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!msZ_!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!msZ_!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 424w, https://substackcdn.com/image/fetch/$s_!msZ_!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 848w, https://substackcdn.com/image/fetch/$s_!msZ_!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 1272w, https://substackcdn.com/image/fetch/$s_!msZ_!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!msZ_!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png" width="1456" height="593" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:593,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:586183,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:false,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/191951866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!msZ_!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 424w, https://substackcdn.com/image/fetch/$s_!msZ_!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 848w, https://substackcdn.com/image/fetch/$s_!msZ_!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 1272w, https://substackcdn.com/image/fetch/$s_!msZ_!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4c09a1fa-e664-4396-ae97-48adea6e1871_2864x1166.png 1456w" sizes="100vw"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><p>Here is the <strong>side-by-side comparison</strong> showing how NIAGARA was &#8220;rewarded&#8221; as compared to AMBASSADOR.</p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!Vx-k!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!Vx-k!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 424w, https://substackcdn.com/image/fetch/$s_!Vx-k!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 848w, https://substackcdn.com/image/fetch/$s_!Vx-k!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 1272w, https://substackcdn.com/image/fetch/$s_!Vx-k!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!Vx-k!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png" width="1456" height="979" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:979,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:739927,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/191951866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!Vx-k!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 424w, https://substackcdn.com/image/fetch/$s_!Vx-k!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 848w, https://substackcdn.com/image/fetch/$s_!Vx-k!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 1272w, https://substackcdn.com/image/fetch/$s_!Vx-k!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F560b9964-677c-46ba-86c4-e8e9b0e316e8_2450x1648.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a></figure></div><h3>The subsequent therapy data from NIAGARA are now available in the IQWiG assessment report!</h3><p>Even though the discussion with the NIAGARA trialists during the first presentation in September 2024 suggested that post-protocol access to immune checkpoint inhibitors <strong>would likely be low</strong>, we were awaiting for those data until very recently. </p><blockquote><p><strong>They are still, to my knowledge, unpublished.</strong> </p></blockquote><p>However, NIAGARA was recently evaluated by IQWiG. In their assessment, some key subsequent therapy data are now reported. Based on those, we can also compare them to AMBASSADOR (see table below).  </p><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!jQ-k!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!jQ-k!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 424w, https://substackcdn.com/image/fetch/$s_!jQ-k!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 848w, https://substackcdn.com/image/fetch/$s_!jQ-k!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 1272w, https://substackcdn.com/image/fetch/$s_!jQ-k!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 1456w" sizes="auto, 100vw"><img src="https://substackcdn.com/image/fetch/$s_!jQ-k!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png" width="2688" height="1166" data-attrs="{&quot;src&quot;:&quot;https://substack-post-media.s3.amazonaws.com/public/images/4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:1166,&quot;width&quot;:2688,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:269770,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:&quot;image/png&quot;,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:&quot;https://www.theoncologyshot.com/i/191951866?img=https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2Fb559ec42-7328-4d17-a908-1ebfdeb55954_2868x1710.png&quot;,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!jQ-k!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 424w, https://substackcdn.com/image/fetch/$s_!jQ-k!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 848w, https://substackcdn.com/image/fetch/$s_!jQ-k!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 1272w, https://substackcdn.com/image/fetch/$s_!jQ-k!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F4dcb90b9-d583-4d4a-90ee-e77c8052d184_2688x1166.png 1456w" sizes="auto, 100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"><button class="pencraft pc-reset pencraft icon-container restack-image buttonBase-GK1x3M" tabindex="0" type="button"><svg aria-hidden="true" width="20" height="20" viewBox="0 0 20 20" fill="none" stroke-width="1.5" stroke="var(--color-fg-primary)" stroke-linecap="round" stroke-linejoin="round" xmlns="http://www.w3.org/2000/svg" class="icon-noB79L"><g><path d="M2.53001 7.81595C3.49179 4.73911 6.43281 2.5 9.91173 2.5C13.1684 2.5 15.9537 4.46214 17.0852 7.23684L17.6179 8.67647M17.6179 8.67647L18.5002 4.26471M17.6179 8.67647L13.6473 6.91176M17.4995 12.1841C16.5378 15.2609 13.5967 17.5 10.1178 17.5C6.86118 17.5 4.07589 15.5379 2.94432 12.7632L2.41165 11.3235M2.41165 11.3235L1.5293 15.7353M2.41165 11.3235L6.38224 13.0882"></path></g></svg></button><button class="pencraft pc-reset pencraft icon-container view-image buttonBase-GK1x3M" tabindex="0" type="button"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" viewBox="0 0 24 24" fill="none" stroke="currentColor" stroke-width="2" stroke-linecap="round" stroke-linejoin="round" class="lucide lucide-maximize2 lucide-maximize-2 icon-noB79L"><polyline points="15 3 21 3 21 9"></polyline><polyline points="9 21 3 21 3 15"></polyline><line x1="21" x2="14" y1="3" y2="10"></line><line x1="3" x2="10" y1="21" y2="14"></line></svg></button></div></div></div></a><figcaption class="image-caption">NIAGARA subsequent therapy data from IQWiG assessment report. </figcaption></figure></div><p>A common, yet misleading, argument is to use real-world data (often involving frailer patients) to explain the low rates of post-protocol care in trials, when the underlying cause is limited global access. A more appropriate comparison is with trials such as AMBASSADOR, which are highly valuable to illustrate what can be expected as optimal subsequent therapy in a clinical trial setting.</p><p><strong>Here, we can derive two conclusions for patients in the control group of NIAGARA:</strong> </p><ol><li><p>confirmation of a very <strong>limited access to checkpoint inhibitors</strong>, received by <strong>only 25% of patients with an EFS event</strong>. </p></li><li><p>a <strong>limited access to any subsequent therapy, </strong>38% of patients with an EFS event  in NIAGARA, significantly lower than 57% of patients with a DFS event in AMBASSADOR.</p></li></ol><blockquote><p><strong>Both may have biased the trial toward an overall survival gain in NIAGARA.</strong></p></blockquote><h3>Why we should follow IQWiG and other HTA bodies reports.</h3><p>It should be noted that other HTA bodies may also be providing key data. In the case of NIAGARA, the CDA-AMC Canadian agency also reported subsequent therapy in their report (<a href="https://www.cda-amc.ca/sites/default/files/DRR/2025/PC0414_Imfinzi_Supplemental_Material.pdf">available here</a>, Table 8). </p><p>A specificity is that IQWiG is also systematically requiring the <strong>first subsequent treatment as well</strong>. Subsequent therapy data lacking granularity can confuse their interpretation (we have written about this together with <span class="mention-wrap" data-attrs="{&quot;name&quot;:&quot;Vinay Prasad&quot;,&quot;id&quot;:21798998,&quot;type&quot;:&quot;user&quot;,&quot;url&quot;:null,&quot;photo_url&quot;:&quot;https://substackcdn.com/image/fetch/f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fsubstack-post-media.s3.amazonaws.com%2Fpublic%2Fimages%2F8d9b3de5-2e57-4d32-a0d4-99f8431caa20_8688x5792.jpeg&quot;,&quot;uuid&quot;:&quot;666e1fd1-93af-4c15-8c5e-9229392b8856&quot;}" data-component-name="MentionToDOM"></span>, see <a href="https://drive.google.com/file/d/1n391SflYCIDtbeFMXndIebp61y2XKWKm/view?pli=1">here</a>)</p><p>The sponsors, when submitting a dossier to IQWiG, must specifically provide :  </p><blockquote><p><em>&#8220;details regarding <strong>subsequent treatments</strong> administered after discontinuation of the study medication (for oncology-related issues, please also provide separate details regarding the <strong>first subsequent treatment</strong>).&#8221;</em></p></blockquote><p>They are also requiring, systematically, the numbers of censored patients: </p><blockquote><p><em>&#8220; In survival analyses, the Kaplan-Meier curve should be plotted, including information on patients at risk and the proportion of censored patients over time (at multiple time points). A separate Kaplan-Meier curve should be plotted for each endpoint for which such an analysis is performed.&#8221;</em></p></blockquote><p>IQWiG is doing an outstanding work. Their reports, which are publicly available, are usually translated into English a couple of months after publication. English reports are <a href="https://www.iqwig.de/en/">available on the IQWiG website, switching to english language, and searching for the relevant drugs</a>. Definitely worth following closely!</p><div class="subscription-widget-wrap-editor" data-attrs="{&quot;url&quot;:&quot;https://www.theoncologyshot.com/subscribe?&quot;,&quot;text&quot;:&quot;Subscribe&quot;,&quot;language&quot;:&quot;en&quot;}" data-component-name="SubscribeWidgetToDOM"><div class="subscription-widget show-subscribe"><div class="preamble"><p class="cta-caption">Thanks for reading The Oncology Shot with Timothee Olivier! Subscribe for free to receive new posts and support my work.</p></div><form class="subscription-widget-subscribe"><input type="email" class="email-input" name="email" placeholder="Type your email&#8230;" tabindex="-1"><input type="submit" class="button primary" value="Subscribe"><div class="fake-input-wrapper"><div class="fake-input"></div><div class="fake-button"></div></div></form></div></div><p></p><p></p><p></p><p><br></p><p><br><br><br></p><p></p><p></p>]]></content:encoded></item></channel></rss>